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ABSTRACT 
Smoking is associated with an increased morbidity and mortality from 
various diseases of the body. It predisposes to chronic bronchitis, 
emphysema, cerebrovascular accident, tumours of the lung, 
gastrointestinal system, urinary tract, pancreas, etc. Microalbuminuria 
has been shown by many studies as a strong independent risk factor for 
cardiovascular disease. It also predicts the future risk of renal failure and 
is a marker of endothelial injury. Various studies have shown that 
smoking causes a dose dependent increase in urine albumin excretion. 
The aim of this study is to study the proportion of  non-diabetic 
normotensive smokers with increased urine albumin and albumin 
creatinine ratio in an analytical cross sectional study. Our study 
population comprised of 120  non-diabetic normotensive and non-obese 
subjects taken from the general medicine outpatient clinic of 
government rajaji hospital. Relevant history and clinical examination 
was done. Smoker was defined as the one who had a smoking history of 
five or more pack years. Out of 120 patients 76 were smokers and 44 
were non-smokers. The 44 non-smokers were age matched and taken as 
control. Fasting blood sugar, urea, lipids and one time screening of 
urinary albumin and urinary creatinine was done to exclude other 
comorbidities. In our study we found that smokers had significantly 
higher levels of urine albumin and albumin creatinine ratio when 
compared to non-smokers. 69(90.8%) smokers and 7(15.9%) non-
smokers had microalbuminuria. 63(82.9%) of smokers and 2(4.5%) of 
non-smokers had high urinary albumin creatinine ratio(ACR).  The 
mean urinary albumin in smokers was 47.32mg/L and in non-smokers 
was 18.94mg/L. The mean urinary albumin creatinine ratio in smokers 
was 74.06micro g /mg and in non-smokers was 20.65micro g /mg. 
Microalbuminuria and urine albumin creainine ratio(ACR) were directly 
related to the amount of smoking in pack years. The high density 
lipoprotein was significantly reduced in smokers when compared to 
non-smokers(mean HDL in smokers 36.66mg/dl). The two groups were 
comparable in all other parameters.  
 
 
 
 
 
 
 
 
 
KEYWORDS 
MICROALBUMINURIA, SMOKING, URINE ALBUMIN 
CREATININE RATIO (ACR), PACK YEARS, HIGH DENSITY 
LIPOPROTEIN, END STAGE RENAL DISEASE. 
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INTRODUCTION 
Smoking damages the vascular and various hormonal systems of the 
human body. It also plays a major role in thrombus formation, atheroma 
formation and occlusion of vessels. The smoke that emerges from a burnt 
tobacco contains not only nicotine but also more than 4000 chemical 
compounds as a result of pyrolysis and pyrosynthesis of tobacco. The 
smoke contains an aerosol part and a vapour part. The aerosol part gets 
deposited in the airways and also in the alveoli of the lungs. 
Smokers are at a high risk of developing large vessel and small vessel 
atherosclerosis when compared to non-smokers. smokers are also at a 
high risk of developing carcinoma of the larynx, stomach, esophagus, 
pancreas, urinary bladder, ureter, kidney, cervix and other important 
organs. They are also at a high risk of developing haematological 
malignancies such as myeloid leukemia. Smoking also prolongs wound 
healing and causes several complications during pregnancy like placental 
abruption, placenta previa, etc. In women it also leads to early 
menopause. Skin wrinkling, cholelithiasis, impotence and adverse 
cardiovascular events are also caused by smoking. Smoking cessation 
leads to a reduced risk of occurrence of a second cardiovascular event and 
after 15 years of smoking the risk of developing an adverse 
cardiovascular event is almost the same as non-smokers. 
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Microalbuminuria is defined as urinary albumin excretion levels ranging 
from 30 to 300mg/24 hours. Overt albuminuria or macroalbuminuria is 
urinary albumin levels more than 300mg/24hours. Several studies in the 
past have focussed on microalbuminuria as a predictor of cardiovascular 
mortality. It predicts the future development of mortality, doubling of 
serum creatinine and end stage renal disease. Studies have shown that 
prevalence of microalbuminuria is almost double in smokers when 
compared to non-smokers. In diabetic population the smokers have a high 
risk of developing microalbuminuria and progression to proteinuria when 
compared to non-smokers. smoking has four important effects on the 
albumin excretion in diabetics, 
1) Risk of developing microalbuminuria is increased. 
2) Time period between onset of microalbuminuria and the diabetes is 
reduced. 
3) Increases the rate of progression to persistent proteinuria 
4) Increases the rate of progression to end stage renal failure 
5) Increases the risk of development of ischemic nephropathy. 
Our study is to aimed at finding put the proportion of non diabetic 
normotensive smokers having microalbuminuria when compared to 
non smokers and also the effect of smoking on urine albumin 
creatinine ratio. 
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AIM OF THE STUDY 
To study the proportion of non-diabetic normotensive smokers 
having micro-albuminuria and increased urinary albumin-creatinine 
ratio (ACR) in an analytical cross sectional study.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
4 
 
REVIEW OF LITERATURE 
Tobacco smoke is a complex mixture consisting of over 5000 
chemical compounds. These various compounds affect almost all systems 
of the human body. WHO estimates about 5.4 million premature deaths 
are due to smoking world wide. The most common causes of death due to 
smoking are cardiovascular disease, lung cancer and chronic obstructive 
pulmonary disease. 
Here are some of the components and their harmful effects on the 
body, 
1,3 butadiene  Reproduction. 
Acetaldehyde. Nasal olfactory epithelial lesions. 
Acetone. Nervous system. 
Acrylonitrile. Respiratory system. 
Ammonia. Respiratory system. 
Carbon monoxide. Central nervous system. 
Chloroform. Liver damage. 
Copper. Lung and immune system. 
Ethyl benzene. Liver and kidney. 
Hydrogen cyanide. Thyroid and nervous system. 
Mercury  Nervous system. 
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Nickel. Lung fibrosis. 
Methyl chloride. Cerebellum. 
Phenol. Lung, kidney, liver, CVS. 
Toluene. Colour vision, nervous system. 
Tri ethyl amine. Liver, kidney, nervous system. 
Selenium. Respiratory system. 
Cresol. Neurotoxicity. 
Xylene. Respiratory and nervous system. 
Cresol. Neurotoxicity. 
Nicotine. Cardiovascular, renal, lungs, etc. 
2-nitropropane. Liver. 
Acetonitrile. Multisystem. 
Acrolein. Nasal lesions 
Acrylic acid. Respiratory system. 
Aniline. Immune-related. 
Benzene. Decreased lymphocyte count 
Chromium Lower respiratory tract. 
Cobalt. Lung and immune system. 
Diethyl formamide Digestive system 
Hexane. Nervous system. 
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Formaldehyde. Nasal irritation. 
Hydrazine. Liver. 
Isopropyl benzene. Kidney, adrenals. 
Lead. Nervous sytem 
Manganese. Neurobehavioral. 
Methyl ethyl ketone  Nasal effects. 
Nickel. Lung fibrosis. 
Propionaldehyde. Atrophy of olfactory epithelium. 
Pyridine. Odour threshold. 
Styrene Nervous system. 
Vinyl acetate  Nasal lesions 
Propyl benzene Increased organ weight 
 
The TTC (threshold of toxicological concern) is a human exposure 
threshold below which there would be no appreciable risk to human 
health, despite the absence of chemical-specific toxicity data. It is usually 
a cut-off value based on experimental data. The FDA human TTC for oral 
exposure is 1.5 micrograms/day. 
Smoking (cigarettes and beedis) is the third top risk for health loss 
in India, leading to nearly one million deaths every year. Between 1980 
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and 2012, smoking among Indian men decreased from 33.8 per cent to 23 
per cent. 
OXIDATIVE STRESS IN SMOKERS:- 
The oxidative stress produced by smoking can be registered 
directly by measurement of reactive oxygen species production in 
peripheral blood or by the effects of oxidative stress on lipid peroxidation 
products and oxidized proteins or as the responses to the oxidative 
stress
(1)
. 
Effects of this oxidative stress on a variety of vital target molecules 
are more important than the presence of oxidative stress. There are many 
markers for oxidative damage including oxidation and nitration of 
proteins
(1)
. Proteins contain tyrosine residues and the nitration of these 
tyrosine residues leads to production of 3-nitrotyrosine which is a marker 
of nitric oxide dependent oxidative damage. Nitric oxide and 
peroxynitrite mediated formation of 3-nitrotyrosine is elevated in platelets 
and plasma of chronic smokers. Studies have shown higher levels of 
nitrated and oxidized fibrinogen, transferrin, plasminogen and 
ceruloplasmin  in smokers
(1)
. 
Peroxidation of polyunsaturated fatty acids of cell membranes that  
amplify oxidative stress is caused by free radicals from cigarette smoke. 
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The F2-isoprostanes are produced from free radical catalysed lipid 
peroxidation of arachidonic acid. Smokers also contain increased level of 
isoprostane 8-iso-prostagalndin F2 (PGF2). Excretion of urinary 8-epi-
PGF2 excretion was significantly increased in long term current and 
former smokers
(1)
. A does response relationship is present between the 
number of cigarettes smoked and both urinary cotinine and urinary 8-epi-
PGF2 alpha. F2 isoprostane levels  and 8-iso-PGF2 alpha are significantly 
increased in atherosclerotic plaques  as well and this strengthens the 
hypothesis
(1)
. 
Increased levels of malondialdehyde which is a degradation product 
of lipid peroxides have been associated with current smoking status. 
Higher levels of thiobarbituric acid reactive substances(TBARS) have 
been found in smokers compared to non smokers. Studies have shown 
inverse association of  percentage of predicted FEV1 and percentage of 
predicted FVC with TBARS in men and not in women suggesting gender 
differences in the relation of oxidative stress to pulmonary function
(1)
. 
Endogenous levels of antioxidants in the systemic compartment are 
depleted by the exposure to oxidant chemicals in the smoke. Thus 
smoking results in low antioxidant levels in the plasma. Trolox-equivalent 
antioxidant capacity (TEAC) is significantly lower in smokers compared 
to non-smokers.
(1) 
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However studies have found no relationship between plasma levels 
of TEAC and spirometric end points (FEV1 or FEV1/FVC). 
Lower serum levels of vitamin-c, alpha carotene, beta-carotene, 
beta-crytoxanthin, melatonin, alpha-tocopherol, and lutein/zeaxanthin 
have been found in smokers by the THIRD NATIONAL HEALTH AND 
NUTRITION EXAMINATION SURVEY and other studies. In addition 
an inverse relationship between plasma levels of vitamin C and beta-
carotene corrected for habitual dietary intake and cigarette smoking has 
been found
(1)
. Such reduction in plasma antioxidants disturbs the normal 
oxidative-antioxidative balance in smokers. 
Glutathione is a major antioxidant used to maintain vitamins C and 
E in their functional and reduced forms and to eliminate peroxides to 
nontoxic hydroxyl fatty acids
(1)
. The GSH is oxidised to disulphide form 
by the reactive oxygen species present in cigarette smoke resulting in 
decreased GSH levels. 
Similar mechanisms result in an even more extensive oxidation of 
the cysteine /oxidised cysteine redox couple and reduced cys levels 
showing that smoking has additional effects on sulphur amino acid 
metabolism
(1)
. Since cysteine is a critical molecule for normal GSH 
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synthesis, the evaluation of the Cys/CySS redox couple may be a new 
sensitive maker of oxidative stress in smokers
(1)
. 
Elevated levels of peroxides and decreased traditional plasma 
antioxidants characterise the oxidative burden in the systemic 
compartment of smokers. 
SYSTEMIC INFLAMMATION IN SMOKERS: 
Systemic inflammation is characterised by an increase in 
circulatory mediators and activation and release of inflammatory cells in 
to the circulation
(1)
. 
INFLAMMATORY CELLS IN CIRCULATION 
As a result of systemic inflammation the hematopoietic system gets 
stimulated resulting in the release of leukocytes and platelets in to the 
circulation. Long term cigarette smoking increases total WBC counts 
mainly polymorphonuclear cell counts in the blood. There is a does 
response relationship between WBC counts and pack years smoked. 
Other associated changes that occur are the increase in number of 
circulating band cells ( a hallmark of  early marrow release of 
neutrophils) and increased expression of  L-selectin on maturing 
polymorphonuclear cells
(1)
. L-selectin is important for the recruitment of 
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polymorphonuclear cells to the inflamed tissue as it initiates the 
adherence of PMNs to the endothelium
(1)
. 
PMNs from smokers contain higher level of myeloperoxidase 
enzyme. Circulating cytokines such as interleukin-1beta and interleukin-6 
may be responsible for the bone marrow stimulation induced by lung 
inflammation
(1)
. These cytokines can also stimulate the marrow to release 
increased numbers of platelets. 
T-lymphocyte counts are increased in humans exposed to smoke. 
CD4+ cells, CD8+ cells and CD4/CD8 ratio are increased  in heavy 
smokers. Peripheral blood memory T cells and naïve T cells are increased 
in smokers compared to non-smokers
(1)
.  
INFLAMMATORY MARKERS IN PERIPHERAL BLOOD 
Smoking activates inflammatory cells which produce a great 
variety of inflammatory mediators such as acute phase reactants and 
cytokines. Other conditions which produce an increase in cytokine levels 
include infection, trauma, tissue  infarction, cancer, etc. These 
inflammatory mediators are potential markers of persistent and systemic 
systemic alterations. 
These inflammatory mediators are raised in almost all parts of the 
body and are not just confined to the lung
(1)
. There is a strong independent 
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dose-response relationship between elevated levels of  different acute 
phase reactants such as C-reactive protein, fibrinogen and smoking. 
Several studies support the hypothesis that CRP and fibrinogen levels in 
particular are related to pack years of smoking rather than to years since 
quitting smoking
(1)
. 
Studies have shown that CRP levels remain significantly elevated 
even 10 years after smoking cessation. Smoking cessation results in a 
rapid reduction in hemostatic and inflammatory markers, but CRP levels 
remain significantly elevated even after 10 to 19 years and do not revert 
to that of non-smoker levels until after 20 years
(1)
. CRP reduction is based 
on the number of cigarettes smoked. 
Dose response relationship exists between the number of cigarettes 
smoked per day and plasma fibrinogen levels. Reduced lung function per 
se is associated with increased levels of C-reactive protein, blood 
leukocytes and fibrinogen
(1)
. So having both the risk factors (smoking and 
reduced lung function) suggests an additive effect contributing to higher 
levels of systemic inflammation in prone individuals. 
Low FVC is associated with higher plasma levels of haptoglobin, 
ceruloplasmin, alpha1 acid glycoprotein, and higher levels of myocardial 
infarction and cardiovascular death. 
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Large prospective studies have shown increased levels of alpha1 
antitrypsin, haptoglobin, fibrinogen, ceruplasmin, and alpha1 acid 
glycoprotein in healthy adult men with increasing cigarette consumption 
independent of other known cardiovascular risk factors
(1)
. It is also 
possible that high acute phase reactant levels in smokers may have a 
direct on the promotion of cardiovascular diseases. 
Increased levels of CRP and fibrinogen have been associated with 
risk for cardiovascular events. CRP might not only be a biomarker but can 
have direct effects on the pathogenesis of endothelial dysfunction and 
atherosclerosis
(1)
. CRP stimulates endothelin-1 and interleukin-6 
production and upregulates adhesion molecules and sets in motion a 
cascade of events that can lead to clot formation. It has also been shown 
to promote atherosclerosis in lipoprotein-E deficient mice. 
Fibrinogen can promote cardiovascular disease through it effects on 
blood viscosity, fibrin formation and platelet aggregation. Thus CRP and 
fibrinogen levels are markedly increased in smokers possibly contributing 
to pro atherogenic and pro inflammatory effects of chronic smoking. 
Raised acute phase reactant levels partially reflect elevations in 
inflammatory cytokines such as interleukin-6 and tumor necrosis factor
(1)
. 
Similar to acute phase reactants increased levels of pro inflammatory 
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cytokines like interleukin-6 and tumor necrosis factor alpha have been 
shown to be risk factor and predictor for myocardial infarction, stroke and 
coronary heart disease. Several studies have demonstrated raised levels of 
interleukin-6 and tumor necrosis factor levels in smokers
(1)
. 
Studies have shown that interleukin-6 levels were substantially 
increased in current smokers when compared to non smokers. A 
significant association was found between interleukin-6 and WBC counts, 
and interleukin-6 and fibrinogen emphasising the role of interleukin-6 as 
an inducer of fibrinogen 
EFFECTS OF SMOKING ON MARKERS OF HEMOSTASIS, 
COAGULATION AND ENDOTHELIAL DYSFUNCTION: 
There is a complex relationship between smoking and 
atherogenesis which leads to cardiovascular disease. Besides 
inflammation, vascular endothelial dysfunction, systemic hemostatic and 
coagulation disturbances, lipid abnormalities are some other mechanisms 
by which smoking increases the risk of cardiovascular pathology. 
Fibrinogen, tissue plasminogen activator antigen, fibrin d-dimer have 
been identified as predictors of subsequent cardiovascular events
(1)
. 
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Platelet hyper aggregation, activation, plasma viscosity, and 
plasminogen activator inhibitor levels have been associated with 
cardiovascular morbidity and mortality
(1)
. 
Diminished production or availability of nitric oxide causes 
endothelial dysfunction. Smokers have significantly decreased serum 
concentration of nitrate, nitrite, metabolic end products of nitric oxide. 
LDL-low density lipoprotein is more prone to oxidation due to higher 
level of reactive oxygen species
(1)
. 
Oxidised LDL reduces the bioactivity of nitric oxide and this 
reduced bioactivity is strongly associated with increased inflammatory 
cell entry in to the arterial wall. Oxidised LDL is taken up by the 
macrophage scavenger receptors leading to foam cell formation and 
cholesterol ester accumulation. 
Increased platelet/monocyte aggregation and upregulation of 
CD40/CD40L have been proposed as potential contributors to the 
atheroembolic complications of smoking
(1)
. CD40-CD40L ligand couple, 
members of TNF family are expressed by most cells involved in 
atherosclerosis. Smokers have elevated surface expression of CD40 on 
monocytes along with increased CD40L expression on platelet surface. 
Plasma cotinine concentrations correlate with rate of platelet-monocyte 
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aggregations and CD40 and CD40 ligand expressions. A recent study has 
shown the trigger for CD40/CD40L expression in human endothelial and 
smooth muscle cells to be oxidised LDL.
(1) 
Dysfunctional endothelial cells lose their property of non-
adherence to immune effector cells. Smokers have shown to contain 
higher levels of P-selectin, E-selectin and soluble intra cellular adhesion 
molecule (ICAM-1) compared to non smokers. Dose dependent 
relationship exists between daily cigarette consumption, plasma cotinine 
levels, exhaled carbon monoxide levels and plasma ICAM-1 
concentration
(1)
.
 
HEMOSTASIS AND COAGULATION MARKERS: 
Whole blood viscosity and its determinants: haematocrit and 
plasma viscosity, principally composed by plasma fibrinogen and 
lipoproteins are associated with subsequent cardiovascular events. 
Current smokers have increased plasma viscosity and/or haematocrit 
which results in a procoagulant state. Increased fibrinogen levels may be 
the cause of increased plasma viscosity seen in smokers
(1)
. 
Tissue plasminogen activator (t-PA)  which is the main fibrinolytic 
activator that converts plasminogen to plasmin is synthesised from 
endothelial cells
(1)
. Due to the endothelial dysfunction that occurs in 
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smokers there is a major impairment of release of t-PA release from these 
cells. 
The primary inhibitor of fibrinolysis, PAI-I inhibits plasminogen 
activation by binding with t-PA. smoking results in significant increase in 
t-PA antigen which represents PAI-I/t-PA complexes. This indicates 
impaired fibrinolytic activity smokers
(1)
. PAI-I levels are significantly 
higher in smokers and correlates with pack years of smoking. 
Plasmin is responsible for maintain vascular patency by promoting 
degradation of fibrin thrombus and disintegrating clots. Fibrin d-dimer 
levels which are cross liked products of fibrin is related to cardio vascular 
risk
(1)
. Increased D-dimer levels are found in smokers which reflects 
increased coagulation activation because this antigen is produced from 
several degradation products from cleavage of cross-linked fibrin by 
plasmin. 
Smoking is one of the important major life style factor influencing 
levels of a number of novel inflammatory, coagulation and hemostatic 
markers linked to common wide spread diseases in population-based 
prospective studies
(1)
. 
Endothelial dysfunction, low grade inflammation and systemic 
oxidative stress caused by smoking is one of the real working 
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mechanisms that explains increased prevalence of common diseases like 
coronary heart disease, peripheral vascular disease, and chronic 
obstructive pulmonary disease
(1)
. 
Genetic susceptibility also plays a role in smokers developing in 
these diseases. Linkage analysis of extended pedigrees and affected 
sibling pairs, Whole genome association studies and case control are used 
to dissect genetic components of complex traits. 
Disease initiation and progression of the same is based on multiple 
genes interacting with many environmental factors where smoking is only 
one of the variables
(1)
. 
 
SMOKING AND CARCINOGENESIS: 
Cigarette smoking causes over 1 million deaths related to cancer 
per year in the world and about 30% of all cancer deaths in developing 
nations. Lung cancer is the predominant malignancy caused by smoking. 
At the beginning of 20
th
 century lung cancer was rare, but the incidence 
and mortality rate increased progressively as smoking became more 
popular
(9)
. 
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The relationship between researched cigarette smoking and cancer 
is probably the most researched topic in the history of cancer 
epidemiology. The strongest determinant of  lung cancer in smokers is 
duration of smoking, and as the number of cigarettes smoked increases so 
does the risk
(9)
. Smoking increases the risk of all types of lung cancer 
such as small cell carcinoma, squamous cell carcinoma, adenocarcinoma 
(including bronchiolar-alveolar carcinoma) and large cell carcinoma. 
In the united states adenocarcinoma has replaced squamous cell 
type of cancer as the most common type of cancer caused by smoking. In 
india however squamous cell carcinoma remains as the most common 
type of lung cancer
(9)
. 
History of smoking was found in 87% of the males and 85% of the 
females with lung cancer. 
Following are the percentage of tobacco related products smoked in 
india:- 
1) Bidi- 28.4% to 79% 
2) Cigarettes- 9.0% to 53.7% 
3) Mixed-7.5 to 13.6% 
Relative risk of developing lung cancer is 2.23 for cigarette 
smokers and 2.64 for bidi smokers with 2.45 as the overall RR. Bidi is 
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more carcinogenic when compared to cigarettes and this has been shown 
by studies by jussawalla & jain (1979) and pakhala. Hooka smoking has 
also  been shown to be associated with lung cancer
(9)
. 
A recent study has shown smoking of bidi, cigarettes and hookah 
had similar ORs for cumulative consumption  
Environmental tobacco exposure is a well known carcinogen 
associated with lung cancer. According to a meta analysis of 40 studies 
environmental tobacco exposure carries a relative risk of developing 
cancer of 1.48 (1.13-1.92) in males and 1.2 in females(1.12-1.29)
(9)
. with 
more exposure comes more relative risk. Work place exposure to 
environmental tobacco results in  a relative risk of 1.16. 
Childhood exposure to enviromnetal tobacco carries a OR of 3.9. 
there is increasing risk with increasing number of smokers  and duration  
of  exposure. Rapiti et al has also shown that childhood exposure to 
environmental tobacco is associated with the risk of developing lung 
cancer
(9)
. Odds ratio for women was 5.1 in that study. Asbestos, nickel, 
arsenic, radiation, haematie hard rock mining, chromium, chloromethyl, 
ester and mustard gas, soot and tar exposure are some other risk factors 
for lung carcinoma and smoking combined with these risk factors 
increases the risk greatly. 
21 
 
Cessation of smoking avoids the further increase in risk of 
carcinoma regardless of age. Risk of ex-smokers remains high for many 
years even after the cessation of smoking compared to the risk of never 
smokers
(9)
.  
Cigarette smoking is also a major risk factor of transitional cell 
carcinomas of ureter, bladder and renal pelvis. Similar to lung cancer the 
risk increases with the number of cigarettes and the duration of smoking 
and cessation avoids any further raise in the risk. Smoking is also 
associated with renal cell carcinoma
(9)
. Smoking is also associated with 
carcinomas of the oral cavity including the tongue and lip in both men 
and women. Smoking combined with alcoholism further increases the risk 
of oral cavity carcinomas. 
Cigarette is smoking is also the risk factor of nasopharyngeal and 
sinonasal cancer. It is risk factor for hypopharyngeal carcinoma and the 
duration  and  number of  cigarettes smoked increases the risk as in other 
carcinomas. Cigarette smoking also causes squamous cell carcinoma of  
the esophagus and adenocarcinoma of thr esophagus which has been 
increasing. The risk increases with increasing duration of smoking and 
risk remains elevated even after smoking cessation
(9)
. 
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Laryngeal carcinoma is also caused by cigarette smoking and the 
risk increases with duration of smoking and the number of cigarettes 
smoked. Risk is greatly enhanced by alcohol consumption and decreases 
upon stopping smoking. Cigarette smoking is also a cause of liver cancer 
independent of hepatitis B, hepatitis C and alcoholism. Most studies show 
a relationship to cessation and dose. Smoking is also a cause of squamous 
cell carcinoma of the cervix
(9)
. 
Cigarette smoking is also related to myeloid leukemia. Carcinomas 
of hypopharynx, larynx, esophagus, oral cavity, oropharynx are strongly 
associated with cigar and/or pipe smoking. Does response relationship has 
been established by studies. Pipe/cigar smoking is also related to 
pancreas, urinary bladder and stomach carcinomas
(9)
. 
Carcinogens in smoke:- 
A carcinogen is any agent that causes cancer or increases the 
incidence of cancer. The range of total exposure to carcinogens in 
smokers is approximately 1.4-2.2mg/cigarette. Strongest carcinogens such 
as polycyclic aromatic hydrocarbons, N-nitrosamines and aromatic 
amines occur in the lowest amounts while weaker carcinogens such as 
acetaldehyde, isoprene,etc occur in higher amounts
(9)
. 
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PAH were first identified as carcinogenic constituents of coal tar 
and they are incomplete combustion products. They occur as mixtures in 
broiled foods, soots, tars, automobile engine exhaust, and other material 
created by incomplete combustion. PAH are usually locally acting 
carcinogens, for example benzopyrene has powerful local carcinogenic 
activity
(9)
. Mouse skin  has been used to evaluate the carcinogenicity of 
PAH. PAH also causes cancer of lung, mammary glands, trachea 
depending on the route of administration. 
Nitrogen containing analogues of  PAH and compounds such as 
furan  are heterocyclic compounds. Furan is a liver carcinogen. N-
nitrosamines are another huge class of carcinogenic agents which has 
demonstrated activity in over 30 different animal species. They are potent 
systemic carcinogens that affect various tissues. N-nitrosamines 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-
nitrosonornicotine (NNN) are tobacco specific nitrosamines found only in 
tobacco products
(9)
. 
NNK causes lung tumors in many almost all animal species on 
which it is tested on and has particularly high activity in rat. NNN can 
also induce tumors of liver, nasal cavity, and pancreas
(9)
. NNN also 
predisposes to respiratory tract tumors, nasal tumors, and esophageal 
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tumors. NNN and NNK have been shown to induce all these tumors in 
humans
(9)
. 
2-naphthyl amine and 4-aminobiphenyl are aromatic amines first 
classified as human carcinogens due to exposures to due in industries. 
They both are combustion products and all well known to cause human 
bladder carcinoma
(9)
. Broiled foods contain heterocyclic aromatic amines 
which as also combustion products found in cigarette smoke. 
 Aldehydes such as acetaldehyde and formaldehyde are also potent 
carcinogens found in tobacco smoke. They are also endogenous 
metabolite in human blood. Phenolic compounds such as caffeic acid and 
catechol also harbour carcinogenic potential. Glandular tumors of the 
stomach can be caused by relatively high doses of catechol. 1,3-butadiene 
and benzene are two very strong carcinogens present I cigarette and they 
are both multi-organ carcinogens
(9)
. 
Vinyl chloride and ethylene oxide are other important carcinogens 
found in smoke in substantial quantities. Malignancies of the lymphatic 
and hematopoietic system are cause by ethylene oxide. Diverse metals are 
also found in smoke. cigarette smoke contains substantial amount of free 
radicals. Quinone-hydroquinone is a major free radical complex
(9)
. 
Studies have shown that cigarette smoke consists of an uncharacterised 
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ethylating agent with ethylated haemoglobin and DNA paving the way for 
carcinogenesis.  Although there are various well characterised 
carcinogens in cigarette smoke PAH, benzene, ethylene oxide, aldehydes 
and aromatic amines are the most important due to their high carcinogenic 
potency
(9)
. 
Table- carcinogens and tobacco induced cancers 
CANCER TYPE LIKELY CARCINOGEN 
1) Lung 
 
 
2) Larynx 
3) Nasal 
 
4) Esophagus 
5) Liver 
6) Pancreas 
7) Leukemia 
8) Cervix 
9) Bladder 
 
PAH, NNK, aldehydes, 1,3-
butadiene, isoprene, ethyl carbamate, 
benzene, ethylene oxide 
PAH. 
NNK, NNN, aldehydes and other 
nitrosamines. 
NNN, other N-nitrosoamines. 
NNN, other nitrosamines, furan 
NNAL, NNK 
Benzene 
NNK, PAH 
4-aminobiphenyl 
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MECHANISMS OF TUMOR INDUCTION BY CIGARETTE 
SMOKE:- 
The major established pathway of cancer causation by cigarette 
smoking involves exposure to carcinogens, the formation of covalent 
bonds, formation of DNA adducts and the resulting mutations in critical 
genes of somatic cells
(9)
. Somatic mutations do not affect their 
descendants since somatic mutations occur only in somatic cells. The 
somatic mutation theory of cancer is well established and the presence 
various different type of carcinogens in cigarette smoke is consistent with 
the theory. 
People usually start smoking as teenagers generally due to peer 
pressure
(9)
. Some get addicted to nicotine and some smoke habitually. 
However nicotine is not the carcinogenic component of smoke. Each puff 
of cigarette contains a mixture of various different type of carcinogens 
along with thousands of other type of compounds. 
Most of  cigarette smoke carcinogens require to be activated before 
they can function as carcinogens and this activation is metabolic and 
generally catalysed by cytochrome P450 enzymes which convert them to 
electrophilic entities. These electrophilic compounds covalently bind to 
DNA , forming DNA adducts
(9)
. 
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P450s such as 1A1 and 1b1 are induced by cigarette smoke via 
interactions with receptors of aryl hydrocarbon. These p450s play a 
crucial role in the metabolic activation of PAH. The inducibility of these 
enzymes is a critical aspect of cancer susceptibility in smokers. P450s 
such as 2A13, 2E13, 1A2 and 3A4 also play a crucial role in the 
activation of carcinogens from cigarette smoke
(9)
. 
Metabolic detoxification is a process that results excretion of 
carcinogenic metabolites in harmless forms. This is catalysed by enzymes 
such as UDP-glucuronosyl transferases and glutathione-S-transferases. 
Metabolic detoxification and metabolic activation mechanisms compete 
with each other
(9)
. The balance between carcinogen detoxification and 
activation varies among individuals and those with lower detoxifying 
capacity are at a higher risk and those with a higher detoxifying capacity 
are a lower risk for developing cancer. 
The formation of DNA adducts due to the metabolic activation of 
carcinogens are absolutely central to the carcinogenic process. various 
studies 
have
 demonstrated that DNA adduct levels in the lung and other 
tissues are higher in smokers than in non-smokers using relatively non-
specific adduct measurement methods
(9)
. Some studies have shown that 
higher adduct levels are linked to higher probability of cancer. 
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When adduct levels increase in the body cellular repair mechanisms 
remove them and return the DNA structure back to normal. Various repair 
mechanisms exist such as excision of DNA damage by base, nucleotide 
excision repair, mismatch repair, direct base repair by alkyltranferases 
and double strand repair
(9)
. If these enzymes are damaged for example due 
to DNA damage or for other reasons they are unable to carry out their 
function then the adducts will persist, accumulate leading to a high risk of 
cancer. There are also polymorphisms in some DNA repair enzymes that 
lead to a deficient repair enzyme leading on to a high risk of cancer 
development. 
Persistent DNA adducts lead to miscoding during DNA replication  
when incorrect processing by DNA polymerases occur. There is a high 
specificity in the relation between the types of mutation and the DNA 
adducts produced by cigarette smoking. G to A and G to T mutations are 
frequently observed
(9)
. 
In cigarette smoke induced cancers mutations in the KRAS 
oncogene in lung cancer and TP53 tumor suppressor gene are frequently 
observed. Many studies have established the cancer causing role of these 
genes. In lung cancer the metabolically activated PAH causes damage to 
DNA leading on to mutations in TP53 and KRAS genes which predispose 
to lung cancer
(9)
. 
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Cigarette smoking strongly linked with chromosomal damage 
damage throughout the airway tract and digestive tract and numerous 
mutations have been observed in lung cancer. Mutations lead to genomic 
instability, cellular proliferation and cancer due to loss of normal cellular 
growth control functions
(9)
. These mutations act through a complex 
process of signal transduction pathways. Programmed cell death or 
apoptosis is a process that removes cells with DNA damage ad serves as a 
counter measure to these mutational events. The balance between 
mechanisms supressing apoptosis and leading to it have a profound 
impact on tumor growth. 
Epigenetic pathways also contribute  to carcinogenesis. 
Nitrosamines and nicotine bind to nicotinic and cellular receptors 
resulting in the activation of protein kinase B (also known as Akt), protein 
kinase A and other changes
(9)
. And these changes result in increased 
angiogenesis, increased transformation and decreased apoptosis. 
Cigarette smoke results in activation of cyclo-oxygenase-2 and 
epidermal growth factor. Tumor promoters and other co-carcinogens also 
occur in  tumor smoke. In smokers promoter region on genes undergo 
enzymatic methylation resulting in gene silencing and this another 
important epigenetic pathway
(9)
. 
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If gene silencing occurs in tumor suppressor genes it leads to 
unregulated proliferation. 
SMOKING AND DYSLIPIDEMIA:- 
Cigarette smokers are at increased risk for accelerated or premature 
peripheral, coronary and cerebral atherosclerotic vascular disease. They 
also at increased for myocardial infarction. The risk is one to three fold 
high in smokers
(7)
. Several possible explanations have been given by 
studies for these events. Some of these are increased arterial blood 
coagulation, damage to endothelium of arterial wall and changes in blood 
lipoprotein and lipid concentration. 
Lipoprotein abnormalities are one of the major and essential  risk 
factor for the occurrence of atherosclerotic vascular disease. Many studies 
have shown smokers have a rise in plasma total cholesterol, high low 
density lipoprotein (LDL), high very low density lipoprotein (VLDL), and 
high triglyceride levels. High density lipoprotein levels are decreased in 
smokers
(7)
. 
Many studies have established a definite correlation between lipid 
profile abnormalities and smoking. They have also established a dose 
response relationship between amount of cigarettes smoked, duration of 
smoking and changes in lipid profile
(7)
. 
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Tobacco contains many compounds. Nicotine is one of the main 
compounds. Which can lead to an increase in VLDL, cholesterol and 
triglyceride levels. It also leads to a decrease in HDL levels. Nicotine 
increases the circulating pool of atherogenic LDL through increased 
transfer of lipids from HDL  and reduced clearance of LDL from plasma 
compartment
(7)
. Thus this leads to increased deposition on LDL 
cholesterol in the arterial wall. High density lipoprotein has an inverse 
relationship to the risk of coronary heart disease. Lower the level of high 
density lipoprotein higher is the risk of coronary artery disease
(7)
. 
SMOKING AND DIABETES:- 
Smoking increases sympathetic nerve activity, which increases 
vascular tone and energy expenditure. It also leads to secretion of  
corticosteroids leading on to increased burden on the heart. After decades 
of studies it has been revealed without that chronic smoking leads to high 
risk of developing insulin resistance and many aspects of insulin 
resistance syndromes leading on the development of type 2 diabetes 
mellitus. The risk is independent of nicotine induced vascular events and 
is highly related to degree of smoking
(5)
. 
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It has been reported that heavy smokers had a 61% higher risk and 
those who smoked less than 20 cigarettes per day had a 29% increased 
risk. 
Nicotine on insulin action:- 
Studies have shown that smoking leads to disorders of glucose and 
lipid metabolism such as low HDL and hyperglycemia by reducing 
sensitivity. Cigarette smoking worsens glycemic control in a patient with 
diabetes mellitus. High doses of insulin are needed to achieve glycemic 
control in smokers when compared to non-smokers with diabetes
(5)
. 
Studies conducted in rats have shown that the offspring of nicotine 
treated rats possibly as a result of increase in body fat. The fasting blood 
glucose levels of these off springs were found to be higher than the 
fasting blood glucose of a different group of off springs. In addition the 
glucose levels at 30 and 120 minutes after an oral glucose load were 
significantly high in the offsprings of nicotine treated rats than in the 
offsprings of normal rats
(5)
. 
In another study conducted using nicotine infusion in healthy and 
diabetic volunteers, the insulin levels were not different between the two 
groups but insulin levels were required at higher quantities than before in 
diabetic volunteers. This shows that nicotine is more sensitive in type 2 
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diabetes patients in affecting the action of insulin on raised blood glucose. 
Young smokers also demonstrated reduced insulin mediated glycogen 
synthesis from the muscle
(5)
. 
These findings suggest that nicotine exposure both acute or chronic 
can impair insulin action in smokers not having diabetes and cause known 
diabetic patients to develop insulin resistance leading to higher 
requirement of insulin. 
Nicotine on Beta cells of pancreatic islets:- 
Many studies have shown found neuronal nicotinic acetyl 
cholinergic receptors expressed on many non-neuronal cells which 
include pancreatic islets
(5)
. An endogenous pancreatic mechanism 
modulates the action of basal insulin. Studies have shown that neuronal 
nicotinic acetyl cholinergic receptors use an intraganglionic mechanism to 
modulate insulin secretion. Another study has demonstrated that  the 
mRNA for the subunits of neuronal nicotinic acetyl cholinergic receptors 
are expressed on insulin secreting cells using reverse transcriptase 
polymerase chain reaction. It has been shown that apart from long term 
exposure acute exposures can also cause a reduction in insulin secretion. 
These studies suggest that neuronly nicotinic acetyl cholinergic receptors 
play a vital role in insulin secretion
(5)
. 
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Another study has shown that acute exposure to nicotine in levels 
higher than1 Mmol/L led to reduced high blood glucose mediated inslin 
release. It has further been shown that exposure to nicotine for more than 
48 hours led to inhibition of insulin release even at basal blood glucose 
levels
(5)
. 
These studies prove that nicotinic receptors are present in 
pancreatic islet cells and these receptors play a role in affecting pancreatic 
beta cell function.  The presence of these receptors serve as a switch to 
modulate insulin secretion physiology by cigarette smoking
(5)
. 
It has been shown by many studies conducted in various animals 
that apoptosis of pancreatic beta cells are increased by nicotine. In rats 
nicotine exposure in pre natal period led to impairment of endocrine part 
of the pancreas and it also led to increased adipose tissue development. 
These studies have demonstrated a direct link between fetal nicotine 
exposure and the development of metabolic syndrome. Another study has 
shown that nicotine mediated beta cell apoptosis, loss of beta cell mass, 
etc are carried out through the death receptor pathway of the 
mitochondria
(5)
. This apoptosis of beta cells caused by nicotine leads to 
development of postnatal glucose intolerance and increase in adipose 
tissue leading to obesity. Another study conducted by bruin et al has aslso 
demonstrated the apoptosis beta cells caused by nicotine. This study 
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suggests that high nicotine levels in smoking mothers act via the 
pancreatic neuronyl nicotinic acetyl cholinergic receptors and lead to 
oxidative stress in the islet cells and as a result of this oxidative stress that 
apoptosis of pancreatic islet beta cell occurs
(5)
. 
All studies have indicated that exposure to nicotine in pre or 
neonatal period leads to loss of beta cells of pancreas and thus leading on 
to reduced insulin secretion. Nicotine action on the neuronyl nicotinic 
acetyl cholinergic receptors lead to inflammation, oxidative stress and 
dysfunction on mitochondria. These findings suggest the possible 
mechanisms for the development of insulin resistance in diabetic patients 
who smoke and smokers developing glucose intolerance leading on to 
type 2 diabetes mellitus
(5)
. 
SMOKING AND INFECTION:- 
Smokers are at increased risk of contracting bacterial infections. 
Smoking leads to increased risk of  infections such as tuberculosis, 
pneumonia, legionnaires disease, chlamydial and gonococcal infections, 
helicobacter pylori infection, meningitis, nosocomial and post op 
infections
(8)
. 
Cigarette smoking can increase risk of infections in general by 
three different machanisms which include 
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1) Smoking induced structural and physiological changes. 
2) Smoking related increase in bacterial virulence. 
3) Smoking induced immune system deregulation. 
All these mechanisms can occur one at a time or all three 
simultaneously
 (8)
. For instance cigarette smoking play directly 
affect colonization of respiratory tract by bacteria which leads to 
reduced mucocliliary clearance and at the same time cigarette 
smoke induces bacterial components that play a role in binding of 
the bacteria to the respiratory epithelium and impairing the ability 
of  the respiratory phagocytes to fight against the infection causing 
bacteria
(8)
. 
Smoking related structural changes and changes related to 
physiology occur predominantly in the respiratory tract and 
vascular endothelium. The effect of nicotine in blood vessels are 
different for different vascular beds. For instance cigarette smoking 
causes vasoconstriction in the peripheral arteries but it causes 
vasodilation in cerebral vessels. And in periodontal tissues it 
suppresses the angiogenesis of the related vessels and it is 
reversible in cessation if smoking
(8)
. 
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These suggest that the increased bacterial infection in smoking in 
respiratory tract is due to reduced mucociliary clearance of the 
pathogens and in other systems is due to the reduced effectiveness 
of the immune system due to vasoconstriction and inhibition of 
angiogenesis
(8)
. 
Passive exposure of cigarette smoking in infants is a risk factor for 
sudden infant death syndrome. One of reasons for this is the 
influence of low levels of nicotine and cotinine on the toxins of 
pathogenic bacteria such as enterobacter and staphylococcus. It has 
also been shown that nicotine also exhibits lethal synergy with the 
toxins of pathogenic bacteria present in periodontal tissues. Such as 
fusobacterium. Some studies have also demonstrated that smoking 
is a risk factor for development of reservoir of chlamydia 
pneumonia in the epithelium of respiratory tract. Some studies have  
shown that cigarette smoking increases the growth of common 
bacteria present in the respiratory tract such as staphylococcus 
sanguis. While some other studies have shown that smoking has 
little effect on gram negative bacteria and inhibits the growth of 
gram positive organisms
(8)
. 
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The same studies also report that due to this smokers have reduced 
high risk of developing severe gram negative bacterial colonization 
in the oral cavity. Smoking women are at an increased risk of 
developing bacterial infection. In these women the vaginal 
lactobacillus population decrease and anaerobic bacterial growth is 
facilitated due to the impaired phagocytosis as a result of 
smoking
(8)
. 
Cigarette smoking is capable of affecting neutrophil and monocyte 
function by both indirect and direct mechanisms. As a proof of this 
various innate cell receptor-tobacco agonist couples have been 
identified. The functions of phagocytic and antigen presenting cells 
have been compromised by the tobacco smoke. The generation of 
respiratory burst by neutrophils is reduced by smoking resulting 
defective killing of pathogenic bacteria. Cigarette smoke exposure 
suppresses the response of the innate immune system cells to 
lipopolysaccharide due to down regulation of receptors involved in 
bacterial killing such as TLR-2 and MARCO
(8)
. The innate immune 
system also develop impaired ability to produce free oxygen 
species needed for bacterial killing. Cigarette smoking also impairs 
the ability of dendritic cells to process antigen and their maturation 
is also suppressed
(8)
. This leads to reduced expression of co 
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stimulatory molecules such as MHC class II, CD80 and CD86 
which as required for the antigen processing. The ability to produce 
T cell stimulatory cytokines is also reduced. Which are very 
important in curtailing gram negative bacterial infection 
(8)
. 
In smokers IgG produced against bacteria are reduced and IgE 
levels are raised. B cells require cytokines that are released from T 
helper cells to proliferate, become plasma cells and produce 
immunoglobulins . It has been shown that smoker’s exhibit reduced 
T cell proliferative responses. 
ANATOMY OF THE KIDNEY:- 
  There are two kidneys and they are situated in the retroperitoneal region. 
They are placed on either side of the vertebral column. The lower pole of 
each kidney lies at the level of L3 and the upper pole of each kidney lies 
at the level of T12 vertebra. The weight of each kidney is about 125 to 
175g in males and 115 to a55g in females. The length of each kidney is 
about 11 to 12 cms, width is about 5 to 7.5 cms and the thickness of each 
kidney is about 2.5 to 3cms
(42)
. The medial surface of each kidney 
contains the hilum through which the renal vein, artery , lymphatics, 
nerve plexuses pass in to the kidney. The fibrous capsule surrounding the 
kidney can be removed easily. 
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Renal artery enters in to the hilum of the kidney and divides in to two 
branches, the anterior and posterior respectively. Each anterior branch 
divides in to 3 lobar or segmental or lobar arteries and supplies the 
anterior of kidney. The posterior surface of the kidney is supplied by the 
posterior branch and it rarely gives rise to an apical segmental branch. 
There are no collaterals between the arterial branches. 
Renal parenchyma consists of the renal cortex and renal medulla. 8 to 18 
renal pyramids are present in the medulla. The cortico medullary junction 
houses the base of the pyramids and the apex is placed towards the renal 
pelvis and forms the papilla
(42)
. 
The collecting duct opens in to the papilla. The cortex is about 1cm in 
thickness and it covers the renal pyramid and it extends between the 
pyramids to form the renal columns of bertini. Longitudinal elements 
known as the medullary rays of ferrein extend in to the cortex. The 
medullary rays are composed of the proximal, distal tubules and 
collecting ducts and they form a part of the renal cortex. 
The upper urinary tract is represented by the renal pelvis and it is lined by 
the transitional epithelium. Two or three major calyces extend from the 
renal pelvis
(42)
. Several minor calyces extend from the major calyces and 
extend toward the papillae and drain the urine. The length of the ureters 
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are around 28 to 34cms and they arise from lower part of the renalpelvis 
and open in to the bladder. The wall of the ureters are line by smooth 
muscle and this smooth muscle contracts sequentially to drain to the 
bladder. 
THE NEPHRON:- 
The functional unit of the kidney is the nephron and each kidney consists 
of about 4 lakh to 1.2 million nephrons
(42)
. The parts of the nephron 
consist of renal corpuscle, duct, loop of henle, distal tubule and proximal 
tubule. 
The nephron arises from the metanephric blastema and the collecting 
ducts arise from the ureteric bud. The nephrons are divided in to 2 groups, 
they are the ones with a short loop of henle and the other group with a 
long loop of henle. Cortical nephrons have short loop of henle and those 
from medulla have along loop of henle. The loop of henle has an 
ascending and descending limb. 
RENAL CORPUSCLE:- 
The renal corpuscles contain capillaries lined by endothelial cells, 
mesangial cells with matrix, the parietal and visceral layer of Bowman’s 
capsule with its basement membrane. The diameter of the glomerulus is 
about 200 Mm
(42)
. This diameter varies with location. The ultra filtrate of 
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the plasma is produced by the glomerulus. The filtration barrier consists 
of foot processes of visceral epithelial cells, basement membrane and 
endothelium. 
The glomerular capillaries consist of many fenestrated endothelium, 
numerous intermediate filaments and microtubules are found in the 
endothelium
(42)
. The fenestrations are surrounded by the filaments. The 
reason for the negative charge in the endothelium is podocalyxin. Nitric 
oxide which is a vasodilator and endothelin-1 which is a vasoconstrictor 
are synthesised by endothelial cells. Vascular endothelial growth factor 
(VEGF) is synthesised by visceral epithelial cells and this increases 
permeability of endothelial cells by increasing the formation of 
fenestrations in the endothelium and this is essential for survival and 
rapair of endothelial cells in glomerular pathology. 
The first barrier to prevent the passage of blood components from 
reaching the bowmans space are the endothelial cells. 
VISCERAL EPITHELIAL CELLS:- 
The distance between two podocyte foot processes is 25 to 60 nm
(42)
. This 
is called the filtration slit and it is covered by filtration slit membrane. 
The filtration slit diaphragm consists of a central filament. a main 
component of the filtration barrier is a protein called nephrin. It is the 
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product of the gene NPHS1. Mutation of NPHS1 gene is seen in 
congenital nephrotic syndrome or finnish type. This gene is located in 
chromosome 19. Nephrin protein is seen in the slit diaphragm. The 
nephrin is bound to cytoskeleton By CD2Ap. Congenital nephritic 
syndrome is associated with deletion of this CD2AP. Steroid resistant 
nephrotic syndrome is associated with mutation of a gene coding for the 
protein, podocin. 
Podocalyxin is responsible for the negative charge seen in podcoytes. The 
visceral epithelial cells also contain the heymann nephritis antigen. The 
shape of the foot processes is maintained by podoplanin
(42)
. The visceral 
epithelial cells play a vital role in formation of  the basement membrane. 
MESANGIAL CELLS:- 
The mesangial matrix and mesangial cells constitute the mesangium. The 
mesangial cells are irregularly shaped with elongated cytoplasmic 
processes and contain a dense nucleus. The cells contain many 
microfilaments like actin, actinin and myosin. These mesangial cells 
bridge the gap between capillaries and glomerular basement membrane 
and this prevents capillary distention. 
The mesangial matrix is comprised of collagens and glycosaminoglycans. 
The mesangial cells contains properties of a smooth muscle cell and it 
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represents a specialised pericyte. These cells have contractile properties, 
produce mesasngial matrix and regulates GFR and also have phagocytic 
properties. 
 
GLOMERULAR BASEMENT MEMBRANE:- 
The basement membrane of the glomerulus consists of lamina densa 
which is a dense layer and two thinner layers the lamina rara interna and 
the lamina rara externa. The key component of the basement membrane is 
the collagen IV. The mutations in the genes coding for 3,4,5 collagen 
chains give rise to alports syndrome. The basement membrane has a 
negative charge.  Heparin sulphate and other glycosaminoglycans make 
up the anionic sites in the basement membrane
(42)
. 
PARIETAL EPITHELIAL CELLS:- 
These cells belong to the squamous type of epithelial cells. These cells 
give rise to crescents in rapidly progressive epithelial cells. 
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FIGURE SHOWING THE STRUCTURE OF A GLOMERULUS. 
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JUXTA GLOMERULAR APPARATUS:- 
The juxta glomerular apparatus is a vital part of the kidnay and is located 
at the vascular pole of the glomerulus at the point where the glomerulus 
comes in contact with a part of the thick ascending limb. The vascular 
potion of the juxta glomerular apparatus consists of the afferent arteriole, 
the mesangial region and the efferent arteriole. The macula densa makes 
up the tubular part of  the juxta glomerular apparatus. 
JUXTAGLOMERULAR CELLS:- 
These are the specialised cells that are seen in the walls of areterioles and 
the mesangial region
(42)
. These cells have smooth muscle cell and 
epithelial features. These cells contain granules containing renin and their 
precursors. 
EXTRA GLOMERULAR MESANGIUM:- 
This part is also known as the LACIS or the cells of GOORMAGHTIGH. 
These are in contact with the macula densa and present in between 
afferent and efferent arterioles. 
MACULA DENSA:- 
This forms a part of the thick ascending limb. It consists of columnar cells 
and is a major part of renin- angiotensin system. It plays a major role in 
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regulating glomerular filtration rate, renin secretion and arteriolar 
resistance. 
The changes in sodium concentrations in the tubules are sensed by this 
macula densa and the signal is transferred to the glomerular arterioles to 
control the GFR. The  signal is also transferred to the renin secreting cells 
which are present in the afferent arteriole
(42)
. 
 
 
PROXIMAL TUBULE:- 
It consists of a convoluted portion and a straight portion known as the 
pars recta and begins in the urinary pole. 
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LOOP OF HENLE:- 
This functions as the counter current multiplier and plays a role in the 
concentration of urine. 
DISTAL TUBULE AND COLLECTING DUCT:- 
This plays a role in urine acidification and concentration. 
ALBUMINURIA 
Albuminuria is a well known predictor of poor renal outcomes in patients 
with type 2 diabetes mellitus and systemic hypertension. It has also been 
shown by many studies to be a predictor of cardiovscular outcomes in 
these in diabetic and hyeprtensive populations. Studies have shown that 
reducing albuminuria leads to reduced risk of cardiac and renal events
(11)
. 
 Albuminuria is of five different types, 
1) Microalbuminuria- 30 to 150 mg /24 hours 
2) Mild- 150 to 500mg /24 hours 
3) Moderate- 500 to 3000mg /24 hours 
4) Heavy- 1000- 3000mg /24 hours 
5) Nephrotic range- 3000- 3500 mg /24 hours. 
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METHODS FOR MEASURING URINE PROTEIN:- 
DIPSTICK:- 
This method uses the principle that says that presence of protein in 
a buffer solution causes a pH change which is proportional to the 
concentration of the protein itself. The dipstick contains a protein 
sensitive pH indicator dye and a buffer. The indicator changes 
colour which ranges from pale green to green and blue when the 
stick is moistened with urine containing the proteins. This test is 
more sensitive to albumin and very less sensitive to 
immunoglobulin light chains and globulins
(10)
. Therefore accurate 
quantification methods are necessary. Some of the examples of 
such methods are turbidimetry, dye binding techniques (ex- 
pyrogallol red-molybdate colorimetric method or benzthonium 
chloride method).  
The dipstick results are interpreted as follows 
1)negative- <15mg/L 
2)1+ :30-100mg/L 
3)2+: 100 – 300mg/L 
4)3+: 300 – 1000mg/L 
5)4+: >1000mg/L 
Extremely alkaline urine produces a false postitve result. 
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 Nowadays albumin specific dipsticks are available and these are 
very useful to detect low grade albuminuria. Some strips can also 
measure albumin:creatinine ratio
(10)
. 
Dipstick interpretation in albumin specific dipstick, 
+ = 800mg/L 
++ = 1450mg/L 
+++ = 3000mg/L 
 
TABLE SHOWING THE METHODS FOR MEASURING 
ALBUMINURIA:- 
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FIGURE SHOWING THE PODOCYTE FUNCTION 
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          SULFOSALICYCLIC ACID METHOD:- 
Sulfosalicylic acid precipitates proteins in the urine and the 
turbidity results as a result of this precipitation. This turbidity is 
proportional to the urine protein concentration. This method unlike 
the dipstick method detects albumin, globulins and immunglobulin 
light chains
(10)
.  
This test is rarely used nowadays due to enviromental safety 
concerns. 
24 HOUR PROTEIN EXCRETION:- 
This is the gold standard method. It gives the average of the 
variation of the protein excretion that occurs as a result of circadian 
rhythm and it is the most accurate method for monitoring 
proteinuria during treatment. The disadvantages with this method 
are as follows, 
1) Error as a result of over or undercollection. 
2) Error due to undercollection. 
This method unlike dipstick quantifies total protein rather than just 
albumin and hence his results in the detection of light chains which 
is useful in diagnosing diseases like multple myeloma
(10)
. 
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PROTEIN-CREATININE RATIO:- 
This is an alternative method to 24 hour urine protein
(10)
. The 
advantages in this method are as follows, 
1)not cumbresome 
2)not affected by diuretics or variation in water intake. 
3)the same sample can be used for microbial analysis. 
A strong correlation exists between 24 hour urine protein and 
random urine sample protein creatinine ratio. An elevated protein 
creatinine ratio should always be quntified and confirmed with a 24 
hour urine protein. A normal protein creatinine ratio rules out 
pathological proteinuria. This method is not very reliable for 
monitoring proteinuria during treatment. 
SPECIFIC PROTEIN ASSAYS:- 
Electrophoresis on cellulose acetate or agarose can be used for 
qualitative analysis of urine protein after concentration of the 
protein or by use of stains such as silver and gold which are very 
senstitive
(10)
. SDS-PAGE(sodium dodecyl sulfate-polycrylamide 
gel electrophoresis) identifies different proteins in the urine by 
molecular weight and it is also useful to find out the pattern of 
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proteinuria. Single protein measurement might also be beneficial. 
Neutrophil geltinase associated lipocalin can be used for very early 
detection of acute kidney injury. 
Immunoglobin light excretion is suscpected if the dipstick protein 
is negative but the 24 hour urine protein is elevated. 
Immunofixation is used to confirm this
(10)
. 
Ratio of clearance of IgG to the clearance of transferrin can be used 
to assess the selectivity of proteinuria in nephrotic syndrome. The 
molecular weight of IgG is 160,000 and the molecular weight of 
88,000. Highly selective proteinuria suggests the possiblity of 
minimal change disease. This also prevents responsiveness to 
corticosteroids. Selectivity of proteinuria along with low molecular 
weight protein excretion such as alpha-1microglobulin is reported 
to predict response to therapy and outcome in minimal change 
disease, membraneous nephropathy and focal segmental 
glomerulosclerosis
(10)
. 
MICROALBUMINURIA IN HYPERTENSION AND TYPE 2 
DIABETES:- 
In a study which involved 787 patients in the age group of 18-72 
years it was found that discontinuation of the antihypertensive 
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medications for 4 weeks  led to a prevalence of albuminuria of 8%. 
In another study invovling around 1041 individuals a prevalence of 
around 6% was observed. The individuals in this study were young 
individuals with untreated mild hypertension
(11)
. The LIFE( losartan 
intervention for endpoint reduction in hypertension) study 
involving around 8029 patients with stage II-III hypertension  the 
observed prevalence was 26%. In another study with a cohort of 
376 hypertensives who were untreated with albuminuria defined as 
more than 30mg/24hours.the prevalence was 6% for those with 
albumuria alone and 27% had Left ventricular hypertrophy along 
with microalbuminria. Overall albuminuria was present in 16% of 
the patients. It was also suggested from this study that albuminuria 
is a good ptrdictor of LVH. Significant proportion of long term 
smokers had both LVH and microalbuminuria than non smokers. 
Systolic arterial pressure is a major determinant of 
microalbuminuria. The relationship between these two is steeper in 
men than in women. The relationship between left ventricle and 
systolic arterial blood pressure is somewhat linear. Factors such as 
diabetes and oral contraception influences this relationship
(11)
. 
Various studies have observed that increase in dietary sodium was 
associated with an increase in  steepness of the slope of  the 
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relationship between systolic arterial blood pressure , left 
ventricular mass index or AER. 
Apart from systolic arterial blood pressure smoking, insulin 
resistence and obesity were shown to be associated with a high 
level of urinary microalbumin. Studies have also shown that 
albuminuria is also linked to metabolic syndrome
(11)
. According to 
adult treatment panel 3 the prevalence of albuminuria was higher in 
those with metabolic syndrome. It was also found that albuminuria 
increased the number of components of metabolic syndrome of 
metabolic syndrome.  
In a study conducted by groningen cohort in was observed that 
increasing C-reactive protein values was associated with 
remarkable steepening of the slope of relationship between 
albuminuria and mean arterial pressure. 
Many studies have also found that plama homocysteine levels were 
inversely related to glomerular filtration rate. The higher the level 
of plasma homocysteine, the lower was the glomerular filtration 
rate
(11)
. 
In a study condcuted in patients with mild hypertension it was 
observed with the angiotensin converting enzyme inhibitor 
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enalapril when given for over 12 months brought about a 
significant reduction in albuminuria. This effect was more when 
compared with othe group of drugs like beta blockers, calcium 
channel blockers,etc. In LIFE study it was found that losartan 
brought about a significant reduction in albuminuria when 
compared to beta blockers. This suggests that prevention of end 
organ damage was equally important as reduction of blood 
pressure
(11)
. 
Interestingly in a study by redon st al it was shown that in a group 
of 187 untreated systemic hypertension individuals even after 
followup and treatment with angiotensin converting enzyme 
inhibitors and other classes of drugs there was progression from 
normoalbuminuric to microalbuminuric status. This progression 
was less in individuals treated with angiotensin converting enzyme 
inhibtors. Some of the albuminuria progressors are obesity, high 
blood glucose, high blood pressure, insulin resistance and high uric 
acid levels. 
In the prevention of renal and vascular end stage disease study it 
was observed that GFR was elevated in patients with high normal 
urinary albumin (15 to 30mg/ dl) when it was estimated by 24 hour 
creatinine clearance
(11)
. Macroalbuminuria was associated with 
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reduction in creatinine clearance. In another italian study conducted 
with 1600 subjects no relation ship was found between increasing 
urine albumin and low creatinine clearance. In the prevention of 
renal and vascular end stage disease  study a de novo development 
of  low creatinine clearance(< 60ml/min/1.73m2) was observed in 
4.2 % of the individuals. A multivariate analysis showed that urine 
microalbumin was a good predictor of the risk of developing renal 
insufficiency
(11)
. 
Another study showed that there was a direct relationship between 
increasing urine albumin and the decline in GFR as estimated by 
cockroft gault equation. 
No difference in glomerular filtration rate was found between 
normoalbuminuric and microalbuminuric individuals with systemic 
hypertension. Even an increasing filtration fraction was not 
detected. The vasodilatory response to the administration of 
angiotensin converting enzyme inhibitor captoprin was reduced in 
patients with microalbuminuria. This suggests that 
microalbuminuria may be marker of early renovascular 
dysfunction. It is unknown whether it is the microalbuminuria or 
the hyperfiltration is a precursor for further renal alterations
(11)
. 
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Glomerular filtration rate progressively reduces with advancing 
age.many factors accelrate this decline in glomerular filtration rate. 
It was found by many studies that presence of a concentric left 
ventricular hypertrophy is associated with an increased acceleration 
of age related glomerular filtration rate
(11)
. This similar acceleration 
was also found those with glucose intolerance or diabetes. 
In a study involving 141 patients the decrease in 24 hour creatinine 
clearance after 7 years of followup was 12.1ml/min in 
microalbuminuric and 7.7ml/min in normoalbuminuric 
hypertensive patients and the antihypertensive therapy did not have 
any effect. Interestingly the most signifiant predictor of reduction 
in glomerular filtration rate over time was blood pressure in most 
studies. 
Microalbumuria is a predictor of cardivascular mortality. Many 
studies have shown that the urine albumin values that increase the 
cardiovascular risk were lower than the cut off values that are 
established for the criteria for microalbuminuria. Similar is the case 
for urine albumin creatinine ratio
(11)
. Studies have shown that in 
people aged more that 40 years the  cardiovascular risk was high 
for albumin creatinine ratios of 1.28 to 2mg/mmol. In another study 
the threshold of urinary albumin creatinine ratio was 0.65mg/mmol 
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creatinine  roughly corresponding to an urinary albumin of 5-6 
micro g/min. Another study has demonstrated that 
microalbuminuria and peripheral arterial disease were associated 
with a four fold rise in cardiovascular mortality. This rise was more 
significant for hypertensive subjects when compared to 
normotensive subjects. This study concluded that microalbuminuria 
brought about a rise in cardiovascular mortality through a different 
mechanism than extensive atherosclerosis
(11)
. 
Many studies have looked in to the relationship between renal 
outcomes and microalbuminuria in type 2 diabetic populations. 
It is shown by many studies that in patients with urinary albumin 
concentrations of 30 to 140 Mg/ml more likely developed clinically 
detectable levels of proteinuria (>400 Mg/ml) after a followup period of 9 
years. These findings were supported by another study by berrut et al who 
examined patients with type 2 diabetes and systemic hypertension. The 
glomerular filtration rate fall was more in patients with microalbimunuria 
than normoalnuminuria
(11)
. 
In a study that exmained 1715 patients with hypertension, dibetes and 
proteinuria called the irbesartan diabteic nephropathy trial the risk of 
developing end stage renal failure or the doubling of the serum creatinine 
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concentration occured in those indivduals with doubling of proteinuria. 
The individuals included in this study were people with urinary protein of 
altleast 900mg/24hours and a baseline serum creatinine level of 1.0 and 
3.0mg/dl
(11)
. 
In another study called the reduction of end points in non-insulin 
dependent diabtes mellitus with angiotensin II antagonist losartan study 
which included a population of 1513 patients with diabetes type 2 and 
nephropathy( defined as urinary albumin creatinine ratio of  >300mg/g  
and a serum creatinine of 1.0 to 3.0 mg/dl it was observed that presence 
of albuminuria increased the risk of end stage renal disease. 
A metanalysis has also demonatrated that microalbuminuria is a potential 
risk factor for the development of preogressive kidney disease. 
Several studies have showed that bringing down urine albumin levels by 
inhibiting the renin angiotensin system by drugs results in prevention on 
further detoritaiton  and  preserving of renal function
(11)
. 
The reduction of end points in non-insulin  dependent diabetes mellitus 
with angiotensin antagonist losartan trail showed that adding losartan to 
anti hypertensives taken by anti hypertensive patients resulted in 
reduction of proteinuria 35 % more than in placebo cases. A 50% 
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reduction  in albumin level resulted in the reduction in the risk for end 
stage renal failure by 45%
(11)
. 
Similarly in IDNT trial which included 1715 patients with type 2 diabetes 
and systemic hypertension it was showed that irbesartan caused a 
significant reduction in the risk of serum creatinine doubling when 
compared to the placebo group. It also caused a 23% reduction in the risk 
of progression to end stage renal failure. 
For a 50% reduction in the level of urine albumin excretion the risk of 
doubling of serum creatinine and the progression to end stage renal failure 
was brought down by 50%. 
Both angiotensin converting enzyme inhibitors and angiotensin receptor 
blockers achieve this reduction in urinalry albumin by reducing the 
intraglomerular pressure thus reducing the filtration. 
The microalbuminuria reduction with valsartan study also showed a 
similar result ( urinary albumin excretion rate was 56% at 24 weeks for 
valsartan and 92 % for amlodipine). However blood pressure reductions 
were similar in the two groups
(11)
. Thus the angiotensin receptor blockers 
are very beneficial in preserving renal function and improve renal 
outcomes. Increasing the dose of the angiotensin recetor blocker further 
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improves the renal outcome which is independent of blood pressure 
control. 
The irbesartan in patients with type2 diabetes  and microalbuminuria 
study showed that risk of progression to nephropathy was significantly 
less with using 300mg of irbesartan when compared to 150mg of 
irbesartan
(11)
. The result was achieved after adjusment for the baseline 
blood pressure and microalbuminuria achieved during the study. Given 
these results studies are now going on find out whether doses beyond 
recommended doses can bring about greater reno vascular protection. 
Other potential ways to increase the inhibition of renin angiotensin 
system apart from increasing the dose of angiotensin converting enzyme 
inhibitors and angiotensin receptor blockers is to add an aldosterone 
inhibitor such as spironolactone or eplerenone. 
A strong association exists between microalbuminuria and cardiovascular 
outcomes  in diabtes mellitus type 2. In the heart outcomes prevention 
evaluation study which studied 5545 patients without diabetes and 3498 
patients with diabetes showed that the increased urinary albumin 
increased the relative risk of cardiovascular events. Type 2 diabetic 
people had a relative risk of 1.83 where as the non diabetic people had a 
relative risk of 1.61
(11)
. 
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Albuminuria is an independent risk factor for major cardiovasculr events 
this was demonstrated by the IDNT study. The cardiovascular end point 
in this study were cardi0vascular death, hospitalization for heart failure, 
amputation, cerebrovascular accidents, peripheral and coronary 
revascularisation and non fatal myocardial infarction
(11)
. 
The urinary albumin creatinine ratio was associated with increased risk of 
these cardiovascular endpoints. The reduction of endpoints in non-insulin 
dependent diabetes mellitus with angiotensin II antagonist losartan study 
aslo demonstrated that increased urine albumin was associated with 
increased adverse cardiovascular events. According to this study the 
cardiovascular events were defined as composite of cerebrovascular 
events, first hospitalisation for unstable angina, first hopsitalisation for 
heart failure, peripheral revascularisation, coronary revsacularisation, 
myocardial infarction
(11)
. 
This study also demonstrated that higher the urinary albumin creatinine 
ratio higher is the risk of cardiovascualar end points for example an 
individual with a high baseline albumin creatinine ratio (>3g/g) had a 
1.92 fold higher risk for adverse cardiovascular events. 
Gimerno et al studies 436 patients with diabetes mellitus type 2. He 
classified these patients in to four categories and he found that patients 
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with absent cardiovascular disease but higher microalbuminuria had an 
increased relative risk for cardiovascular disease compared with people 
who had normal urinary albumin and cardiovascular disease. This study 
also showed that in patients who had microalbuminuria alone ,the risk of 
getting a subsequent cardiovascular event was the same as in those who 
have already experienced a carfdiovascular event
(11)
. 
Microalbuminuria is  also a risk factor for advanced cardiovascular 
disease. In a study that studies 330 patients with diabetes and 
microalbuminuria and those without microalbuminuria, it showed that the 
diabetes with microalbuminuria had a higher prevalence of three vessel 
disease when compared to those without microalbuminuria. Many lines of 
studies exist showing that the risk of adverse cardiovascular events 
increases as the urinary albumin excretion progresses from 
microalbuminuria to albuminuria and then proteinuria. This has been 
predominanlty studies in diabetic populations. 
Although many studies have widely established that micralbuminuria is a 
independent risk factor for adverse events in diabetic populations, 
evidence suggests that the presence of  albuminuria is a potent risk factor 
for adverse cardiovascular events in non-diabetic populations as well
(11)
. 
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Im framingham study which studied around  1568 non hypertensive 
patients who did not have diabetes mellitus it was shown that urine 
albumin levels less than the microalbuminuria threshold predicted the risk 
of adverse cardiovascular events
(11)
. In prevention of renal and vascular 
end stage disease study which  was conducted in 6669 nondiabteic 
participants it was shown that microalbuminuria increases the 
cardiovascular disease risk. Some studies have also suggested that the 
relative risk of an adverse cardiovascular event is also increased by 
microalbuminuria similar to high cholesterol levels. Thus the 
microalbuminuria must be viewed with a similar weightage given to other 
cardiovascular risk factors such as high blood sugar, 
hypercholesterolemia and systemic hypertension. 
The prevention of renal and vascular end stage disease showed that the 
usage of fosinopril brought about a significant 26% reduction in urine 
albumin excretion and thus the risk of adverse cardiovascular events. In 
life study it was demonstrated that reduction in urinary albumin creatinine 
ratio reduced the risk for cardiovascular mortality. And thus these 
observations strongly suggest that high urine albumin levels are 
independent predictoes of cardiovascular events and a reduction in their 
level greatly reduces cardiovascular mortality
(11)
. 
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SMOKING AND THE KIDNEY 
POTENTIAL MECHANISMS:- 
Chronic smoking increases the progression of nephropathies. It increases 
the progression from microalbuminuria to macroalbuminuria and then on 
to progressive renal failure in diabetic population. In a large study the 
prevalence of micro and macroalbuminuria was higher in smokers when 
compared to non smokers with diabetes mellitus type II. In a study 
conducted in patients with polycystic kidney disease the proteinuria was 
higher in patients who were smokers
(4)
. 
The time period between median and end stage disease was shorter in 
smokers when compared to non-smokers in patients with lupus nephritis. 
In a study conducted among patients with IgA nephropathy and 
polycystic kidney disease it was found that smoking increased the 
progression to end stage disease if they had not received angiotensin 
converting enzyme inhibitors. This suggests that smoking is a modifiable 
factor in diabetic and non-diabetic populations. 
The effects smoking in people without preexisting disease conditions 
have not been well studied. In study with 24 apparently normal smokers 
and 30 non smokers it was shown that smokers had reduced renal plasma 
flow which was assessed with 51CR-EDTA clearance
(4)
. Another study 
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showed that smoking 120 insulin dependent diabetes patients had higher 
glomerular filtration rates than their non-smoking counterparts. Smoking 
was associated with high urine albumin excretion rates in hypertensive 
patients. Untreated hypertensive  smoking pateints had a two fold higher 
prevalence of microalbuminuria when compared to non smokers. The 
most important factor which determines the microalbuminuria is the 
arterial blood pressure
(4)
. 
In hypertensive patients the reason for microalbuminuria is believed to be 
the transglomerular passage of albumin in most patients. The exception to 
this is primary hyperaldosternism. Hypertensive smokers with 
microalbuminuria have a faster decrease in creatinine clearance when 
compared to normoalbuminuric patients. 
Acute effects of smoking differ with the duration of smoking, habit of 
smoking and with underlying pathology. For example one study has 
demonstrated that oral nicotine administration caused a marked and 
proportional decrease in renal plasma flow and glomerular filtration rate 
in those who have never smoked before where as the same administration 
caused no change in renal plasma flow in chronic smokers
(4)
. 
Contradicting this another study has shown that acute smoking brought 
about a reduction in glomerular filtration rate but did not reduce renal 
plasma flow in individuals who were occasional smokers. Another study 
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demonstrated that acute smoking did not bring about a change in 
glomerular filtration rate in patients with IgA nephropathy. It appears that 
the acute effect of smoking depends on the type of smoking habit
(4)
. 
Arterial pressure rises transiently during and after smoking due to the 
surge of catecholamines. Many studies have shown that as a result of this 
phenomenon smokers are at increased risk of developing malignant 
hypertension when compared to non-smokers. Another effect that 
smoking brings about is a rise in endothelin levels. Other that rise include 
vasopressin,ACTH, thromboxane, etc and all of these play a role in 
progression of nephropathy. 
Smoking leads to an excessive production of free radical and thus 
oxidative stress and the condition is worsened by the reduced levels of 
ascorbic acid in chronic smokers. Smokers exhibit abnormal endothelin 
mediated vasodilatation in  response to nitrates or acetylcholine due to 
endothelial damage brought about by the free radicals. This response 
improved when ascorbic acid was supplememented. one study 
demonstrated that non smokers who were given nicotine gum exhibited 
low urinary levels urinary cGMP which meant low nitric oxide 
production
(4)
. 
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Smoking affects the autonomic nervous system by bringing about 
adrenaline and nor adrenaline release which leads to acute rise in blood 
pressures
(4)
. 
Effects of smoking in the general population:- 
Smoking leads to a increase in urinary albumin excretion. Smoking was 
independently linked with increased albumin excretion rates even in 
nondiabetic normotensive populations. A cross sectional study which was 
done in 7476 non-diabetic individuals showed that albumin excretion 
rates correlated with increasing pack years and that there was a dependent 
association. Smoking increases the risk of  detoriation of renal function 
apart from causing increased albumin excretion. Smoking increases 
creatinine clearence among smokers but the effect is limited to current 
smokers and it reverses among cessation of smoking. Some Studies have 
also found a dose dependent increase of the risk of end stage renal failure 
in smokers
(4)
. 
A prospective study which studied 4142 individuals above age 64 years 
showed that smoking contributed to the doubling of serum creatinine over 
a 3 year time period. Smoking can explain why renal deterioration occurs 
not in all but only in some people.  
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Effect of smoking on patients with primary hypertension:- 
10-25 % of patients with primary hypertension exhibit albuminuria and 4- 
18% of patients with primary hypertension exhibit proteinutria. Smoking 
is an independent predictor for microalbuminuria in patients with 
essential hypertension. This was showed by the heart outcomes and 
prevention study
(2)
.  Another study has found that patients with left 
ventricular hypertrophy, smoking history and hypetension had higher 
prevalence of microalbuminuria when compared to non-smokers. 
Regalado et al did a prospective study with 51 patients of hypertension. 
These 51 patients were followed up for a period of 35 months. And he 
found that increase in serum creatinine occurred despite adequate control 
of blood pressure. This study showed that there were independent factors 
which predicted renal detoriation and they were black ethnicity, higher 
initial base line serum creatinine and smoking. And the most strongest 
predictor among these was smoking. 
Effects of smoking in patients with renal disease:- 
First report that smokers had a higher risk to develop diebetic 
nephropathy came from a study that was conduucted way back in 1978
(2)
. 
This was later confirmed by another study which incuded 668 type 1 
diabetic individuals. Nephropathy was present in around 13% of the 
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people who smoked <10 cigarettes per day whereas it was present in 
>25% in people who smoked more than 30 cigarettes per day
(2)
. There 
after many studies were done in type II diabetes mellitus populations and 
a similar result was obtained. The adverse effect that smoking produced 
on the kidney did not depend upon the age or duration of the disease. And 
this was applicable to both type 1 and type 2 diabetes patients. Another 
study also demonstrated that urinary albumin levels were higher among 
diabetic patients who were smokers. The same study also demonstrated 
that the risk of microalbuminuria was high in the first few months 
following the diagnosis of diabetes mellitus. In another study which 
included 794 individuals showed that dibetic patients who were smokers 
had a higher relative risk for the progression of microalbuminuria to overt 
proteinuria when compared to their nonsmoking counterparts. 
Another study by sawicki showed the odds ratio for the progression of 
diabteic nephropathy defined as a >20% rise in proteinuria and >20% fall 
in glomerular filtration rate with every 10 pack years was 2.74 when 
compared to non-smokers. Diabetes mellitus patients reach end stage 
renal failure faster when compared to people fo other groups
(2)
. 
Another study which studied 16 patients with type 2 diabetes and 16 
patients with type 1 diabtes showed that the rate of decline in creatinine 
clearance at the end of the study was greater in smokers when compared 
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to non-smokers. The rate of decline in smoking patients with diabetes 
mellitus type 2 was 1.21 and in those who were non smokers was 0.73. 
rate of fall in glomerular filtration rate was approximately 56% higher in 
smoking individuals when compared to non-smoking individuals
(2)
. 
Another propective study conducted by chuahirun and wesson revealed 
more information regarding the effect of smoking in diabetes mellitus 
type 2 patients. In this study blood pressure was well controlled according 
to current standards, glycemic control was also good. At the end of this 
study the rise in serum creatinine was significanlty higher in smokers 
when compared to nonsmokers. In this study there were no other 
confounding factors and so smoking was the only factor which caused a 
rise in creatinine. Some retrospective and prospective studies have shown 
that angiotensin converting enzyme inhibitors provide reno protection in 
smoking induced renal damage by way of improving endothelial function 
after angiotensin converting enzyme inhibition. Some of the beneficial 
effect of angiotensin converting enzyme inhibition include scavenging of 
free radicals and removing the cigarette induced suppression of nitric 
oxide
(2)
. Thus smoking clearly has adverse effects on both type 1 and type 
2 diabetes individuals. 
Smoking also affects the progression of non diabetic renal disease. This 
was first suggested by a study on patients with autosomal dominnant 
75 
 
polycystic kidney disease. Then on studies were also done involving 
people with IgA glomerulonephritis
(2)
. These studies suggested that the 
rate of progression to end stage renal failure increased in male smokers 
compared with non smokers and the risk was substantially high in patients 
who did not have a history of treatment with angiotensin converting 
enzyme inhibitors. The reduction in glomerular filtration rate was 
5.3ml/min in heavy smokers and was only 2.3ml/min in non smokers over 
a 3 year follow up. This shows that the smoking status is related to the 
rate of decrease in glomerular filtration rate. Smoking doubles the rate of 
progression of chronic glomerulonephritis. Studies among women do not 
exist widely and in one study which included 246 patients with type1 
diabetes mellituts no relation ship was found between smoking and 
diabetic nephropathy progression and ofcourse large scale studies are 
needed in women. 
Only limited studies are available regarding the effects of smoking on the 
renal disease that occur as a result of systemic diseases. One retrospective 
study which included around 160 patients with lupus nephritis showed 
that smoking was an independent and strong predictor for the progression 
to end stage renal failure
(2)
. The effect of smoking was not dependent on 
the type of immunosuppressive treatment given to these patients or the 
presence of hypertension in these patients. 
76 
 
One other study also suggests that smoking induced endothelial damage 
might pave the way for the formation of antibodies against nuclear 
antigens released from endothelial cells and thus these can lead to the 
development of ANCA positive glomerulonephritis. Smoking also 
increases the risk of alveolar hemorrhage in good pasture syndrome 
patients
(2)
. 
Potential mechanisms of smoking induced injury:- 
1) Rise in sympathetic activity. 
2) Rise in arterial blood pressure and heart rate 
3) Circadian fall in blood pressure during night time is affected 
4) Renal vascular resistance is increased due to reduced renal blood 
flow. 
5) Rise in intraglomerular pressure 
6) Increased hyperfiltration in patients with diabetes 
7) Renal artery atherosclerosis and myointimal hyperplasia of renal 
vascualture 
8) Endothelin and angiotensin mediated proliferation of mesangial, 
endothelial and vascular smooth muscle cells
(2)
. 
9) Toxic effects on the renal tubules 
10) Toxic effects on endothelium such as  
 Altered thromboxane and prostagalndin metabolism 
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 Oxidative stress created by free radicals 
 Reduced nitric oxide levels 
 Dysfunctional vascular dilatation 
 Monocyte adhesion to endothelium is increased. 
 Hypoxia due to carbon monoxide production 
11) Increased aggregation of platelets 
12) Dysfucntional glycosaminoglycan and lipoprotein 
metabolism 
13) Immune dysregulation 
14) Increased anti-diuresis due to increased vasopressin release. 
15) Development of insulin resistance. 
Smoking and renal artery atherosclerosis:- 
Smokers have a higher prevalence of peripheral vascular disease and 
renal vascular stenosis occurs with a higher prevalence in those with 
peripheral vascular disease. Predominant proportion of people with 
unilateral or bilateral renal artery stenosis are smokers
(2)
. Smoking 
accelrates the rate of decline in renal function with renal artery stenosis. 
Apart from damage to the vasculature one another mechanism by 
promoting cholesterol microembolism. Studies have shown that renal 
blood flow decreased progressively with increasing severity of peripheral 
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arterial atherosclerosis. Extra renal atherosclerosis and renal 
hypoperfusion are closely related
(2)
. 
Effects of smoking in renal transplant patients:- 
A cohort study was conducted in the year of 1985 which included about 
645 adult renal allograft recipients. 24% of these patients were smokers. 
smoking before transplant was associated with reduced graft survival in 
the post transplant period. Patients who were smokers before tranplant 
had a graft survival of 48% at the end of 10 years and those who were non 
smokers had a graft survival of 62% at the end of 10 years. For those who 
smoked but quit during the transplant evaluation phase, the death 
censored graft survival was significanlty high when compared to those 
who did not quit smoking. The reduced survival were not explained by 
rejection episodes. Thus smoking cesssation has a major impact on graft 
survival. The extent to which the smoke has impact on the graft may also 
depend on the preexisting disease condtion that caused that end stage 
renal failure in the patient. Smoking induced immune dysregulation are 
particularly detrimental in patients with renal pathology due to immune 
regulation abnormalities such as systemic lupus erythematosus
(2)
. 
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Reversibility of smoking induced damage:- 
Studies have shown that cessation of smoking significantly reduces the 
urine albumin. Of course it goes without saying that this occurs only with 
adequate glycemic control and blood pressure control. Another study has 
shown that progression of renal failure is around 53% in active smokers 
and in the long run this rate falls down to 33 % after smoking cessation
(2)
. 
This is also applicable to non-diabetic renal disease. Risk of 
microalbuminuria in significant in active smokers and it is very mild in 
those who have stopped smoking. The reduction in renal blood flow 
however is not completely reversible  following smoking cessation. 
Pharmacological therapies  available for smoking cessation are nicotine in 
its various forms like patches, gums, sprays, bupropion(dopamine and 
noradrenaline reuptake inhibitor), varenicline (partial agonist of nicotinic 
acetyl cholinergic receptors, clonidine, anxiolytics such as beta blockers, 
benzodiazepines, buspirone, anorectics like fenfluramine and 
phenylpropanolamine and stimulants such as amphetamines and 
methylphenidate. 
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MATERIALS AND METHODS 
 STUDY POPULATION: 
This study was conducted in 120 non-diabetic, normotensive and 
non-obese subjects who were attending the general medicine outpatient 
clinic at government rajaji hospital, Madurai. Out of the 120 patients, 76 
were smokers and 44 were non-smokers. 
CONTROL POPULATION 
Out of the 120 patients, 76 were smokers and 44 non non-smokers. The 
non-smokers were age matched and taken as control group. 
Inclusion criteria: 
1) Age 30 to 70 years. 
2) Normotensive ( ≤139/≤89 mmHg) 
3) Non-obese (body mass index (BMI <30 Kg/m2) 
4) No family history of premature vascular disease 
5) Normal total cholesterol (<200 mg/dl) 
6) Normal renal function (urea ≤40 mg/dl and creatinine  ≤1mg/dl) 
7) Not on any regular cardiovascular medication and given 
informed consent. Clinically stable. 
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 Exclusion Criteria: 
1) age < 30 years and > 70 years. 
2) Diabetes mellitus/ using insulin or hypoglycemic agents. 
3) Hypertensives or using anti-hypertensive medications. 
4) Hyperlipidemic or using lipid lowering drugs. 
5) Obese (BMI ≥30 Kg/m2) 
6) Abnormal renal parameters. 
7) Urinary tract infection. 
8) Significant renal disease or using diuretic drugs. 
9) Angiotensin converting enzyme inhibitors. 
10) Alcohol consumption or other significant drugs. 
11) Fever 
12) Vigorous physical activity 
13) Not willing to give consent. 
PERIOD OF STUDY   : JUNE 2014 TO SEPTEMBER 
                                                              2014. 
TYPE OF STUDY                      :         analytical Cross sectional study 
PARENT DEPARTMENT         :         Department of General Medicine. 
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COLLABORATING                 :        Department of nephrology and 
   DEPARTMENTS                               Department of biochemistry  
                                                  
ETHICAL CLEARANCE  :          Obtained 
CONSENT              :          Individual informed consent.             
 ANALYSIS   :    STATISTICAL ANALYSIS 
CONFLICT OF INTEREST :    NIL 
FINANCIAL SUPPORT :     NIL 
 
PARTICIPANTS: 
120 non-diabetic, normotensive and non-obese subjects were included in 
this study from the general medicine outpatient clinic. A brief history and 
clinical examination were done. Smokers were defined as those who have 
smoked atleast 20 bidi /day for 5 years (5 pack years) or equivalent. 
smokers were classified in to four groups:-  
1) very light smokers  5-9 pack years 
2) light smokers  10-14 pack years 
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3) moderate smokers  15-19 pack years 
4) heavy smokers  >20 pack years. 
Out of 120 subjects in our study 76 (63.3%) were smokers and 
44(36.7%) were non-smokers. All were males. The 44 non smokers 
were age matched and taken as control. The baseline physical 
characteristics and biochemical characteristics of these two groups 
were compared used statistical tests.  
LABORATORY INVESTIGATIONS : 
overnight fasting blood sugar, serum creatinine, serum urea and lipid 
profile were measured. The blood sugar was measured using the glucose 
oxidase and peroxidase method. Serum urea was measured using the 
enzymatic glutamate dehydrogenase method. Serum and urine creatinine 
concentrations were measured using the jaffe’s calorimetric method. The 
urine albumin was measured using turbidimetric method from first 
morning void (timed) mid stream urine samples. Since the turbidimetric 
method and the timed urine sample was used for urine albumin 
measurement the cut off value for microalbuminuria in this study is taken 
as 20 mg/L. In lipid profile total cholesterol was measured using the 
cholesterol oxidase peroxidase method. The triglyceride was measured 
using the glucose 3 phosphate oxidase-peroxidase method. Cholesterol in 
the supernatant is measured after precipitation of apo-B containing 
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lipoprotein by polyethylene glycol to determine the HDL cholesterol. 
LDL cholesterol is estimated by using the friedewald formula and this 
formula appears to be the most practical and reliable method for 
determining LDL-cholesterol in clinical practice.  
LDL cholesterol=Total cholesterol-[HDL+(Triglyceride/5)] 
VLDL is estimated by dividing the plasma triglyceride by 5 reflecting the 
ratio of cholesterol to triglyceride in VLDL particles. 
After obtaining the results, the data was compiled in a Microsoft Excel 
sheet. Statistical analysis was done using IBM SPSS Ver.16 (Statistical 
package for social sciences). Percentage prevalence, Standard deviation 
and ‘p’ values were calculated. Chi – Square test and Student t test were 
used to find out the significance of relationship between cases and 
controls. 
Limitations of the study: 
1. small number of subjects. 
2. single centre study. 
3. only the one timed urine sample was used. 
4. Direct LDL measurement was not done, derived  by friedwald formula 
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RESULTS AND INTERPRETATION 
After applying the inclusion and exclusion criteria 120 cases were 
selected for the study. The age distribution is as follows, 
Table 1: Age distribution of the study population(n=120) 
AGE GROUP SMOKERS 
(n=76) 
NON-
SMOKERS 
(n=44) 
TOTAL 
(n=120) 
30-40 years 12 (15.78%) 8 (18.18%) 20 
41-50 years 35 (46.05%) 24 (54.54)% 59 
51-60 years 27 (35.52%) 11 (25%) 38 
61-70 years 2 (2.63%) 1 (2.27%) 3 
TOTAL 76 44 120 
 
Mean age:- 47.27     S.D:- 6.553 
Maximum:- 64                       
Minimum:-33 
The p value comparing the two means of the study and control 
group was 0.169 and hence the two groups are comparable 
with respect to age. 
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Table 2 .Distribution of the study population according to study 
& control groups (n=120) 
 
 
 
 
 
Table 3. Distribution of smokers according to pack years 
5-9 pack years 45 (59.21%) 
10-14 pack years 15 (19.73%) 
15-19 pack years 12 (15.78%) 
More than 20 pack years 4 (5.26%) 
Total 76 
 
 
 
 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 SMOKERS 76 63.3 63.3 63.3 
NON 
SMOKERS 
44 36.7 36.7 100.0 
Total 120 100.0 100.0  
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CHART 2. Distribution of smokers according to pack years 
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TABLE 4. Descriptive statistics of the biochemical and physical 
parameters between smokers and non-smokers 
Variable Mean S.D Minimum maximum 
smokers Non-
smokers 
BMI 22.128 22.525 1.1176 18.9 24.7 
SBP 
(mm Hg) 
124.16 123.73 4.0000 114 132 
DBP 
(mm Hg) 
75.50 75.61 3.569 70 82 
FBS 
(mg/dl) 
84.95 83.55 6.687 72 98 
TC 
(mg/dl) 
151.62 151.45 4.419 144 163 
LDL 
(mg/dl) 
89.116 84.977 4.978 75 98 
HDL 
(mg/dl 
37.05 42.00 3.835 30 56 
TG 
(mg/dl) 
126.99 123.07 8.500 113 150 
VLDL 
(mg/dl) 
25.397 24.614 1.69 22.6 30 
SERUM  
UREA(mg/dl) 
24.46 25.39 4.637 17 34 
SERUM 
CREATININE 
(mg/dl) 
0.750 0.745 0.0622 0.6 0.9 
CREATININE 
CLEARANCE 
(ml/min/1.72m2) 
102.310 105.355 8.3098 76.5 123.0 
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TABLE 5. Independent samples test for physical and 
biochemical parameters. 
characteristic P value 95% confidence interval 
lower Upper 
BMI 0.060 -0.8119 0.176 
SBP 
(mm Hg) 
0.572 -1.074 1.935 
DBP 
(mm Hg) 
0.867 -1.458 1.231 
FBS 
(mg/dl) 
0.270 -1.104 3.908 
TC 
(mg/dl) 
0.846 -1.501 1.828 
LDL 
(mg/dl) 
<0.001 -5.7234 -2.5536 
HDL 
(mg/dl 
0.001 -6.076 -3.819 
TG 
(mg/dl) 
0.014 0.797 7.040 
VLDL 
(mg/dl) 
0.014 -1.4080 -0.1595 
SERUM  
UREA(mg/dl) 
0.294 -2.665 0.813 
SERUM 
CREATININE 
(mg/dl) 
0.701 -0.189 0.0279 
CREATININE 
CLEARANCE 
(ml/min/1.72m2) 
0.535 -6.1257 0.0360 
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GRAPH 3. Distribution of lipid profile among the study 
population. 
 
In this study smokers had significantly low HDL levels  
to non-smokers. p value was 0.01 and  so the difference in HDL  
between the smokers and non-smokers was statistically significant. 
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TABLE 6. Distribution of microalbuminuria in mg/L among 
the study population 
 
 
 
  
 
 
 
 
 MICROALBUMINURIA 
CATEGORY 
Total <20 >20 
GROUP Smokers Count 7 69 76 
% within 
GROUP 
9.2% 90.8% 100.0% 
Non-
smokers 
Count 37 7 44 
% within 
GROUP 
84.1% 15.9% 100.0% 
Total Count 44 76 120 
% within 
GROUP 
36.7% 63.3% 100.0% 
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GRAPH 4.Graph showing the distribution of microalbuminuria 
among the study population. 
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MEAN URINARY ALBUMIN 
(mg/L) 
5-9 pack years (n=45) 33.38 
10-14 pack years (n=15) 48.84 
15-19 pack years (n=12) 57.19 
>20 pack years (n=4) 171.15 
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TABLE 7. Distribution of mean urine albumin creatinine ratio 
(ACR) in micro g/mg 
 
 
 
   
ACR CATEGORY 
Total 
   
<30 >=30 
GROUP  SMOKERS  Count 13 63 76 
 % within       
GROUP 
17.1% 82.9% 100.0% 
 
NONSMOKER
S 
 Count 42 2 44 
 % within        
GROUP 
95.5% 4.5% 100.0% 
Total Count 55 65 120 
% within 
GROUP 
45.8% 54.2% 100.0% 
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GRAPH 5. Graph showing the distribution of mean urinary albumin 
creatinine ratio. 
 
 
 
PACK YEARS MEAN URINE ACR (micro g/mg) 
5-9 pack years (n=45) 48.92 
10-14 pack years (n=15) 68.74 
15-19 pack years (n=12) 125.77 
>20 pack years (n=4) 221.78 
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TABLE 8. Comparison between mean urine albumin between 
smokers and non-smokers. 
 
GROUP 
N Mean 
Std. 
Deviation P value 
95% confidence 
interval 
 
 
smokers 76 47.3271 31.52392 
<0.001 18.82491-37.94884 Non-
smokers 
44 18.9402 7.04755 
 
The chi square test p value was <0.001 comparing the means of both  
smokers and non-smokers and hence the difference is  
significant. 
 
GRAPH.6 showing the comparison of mean urinary albumin between 
smokers and non-smokers 
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TABLE 9. comparison of mean urinary albumin creatinine ratio 
between smokers and non-smokers. 
 
 GROUP 
N Mean 
Std. 
Deviation P value 
95% 
confidence 
interval 
URINE  
ACR 
(micro g/mg) 
smokers 76 74.0617 49.95803 
<0.001 
38.42963-
68.38061 Non-
smokers 
44 20.6566 4.49084 
 
The chi square p value comparing the two means was <0.001, hence the  
difference was statistically significant. 
 
Graph.7 showing the comparison of urine ACR between smokers and 
non-smokers 
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TABLE 10. showing the smoking group descriptive statistics with 
regard to urine albumin and urine ACR 
 
 
 
 
 
 
  
N Mean 
Std. 
Deviat
ion 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Min Max 
 Pack 
years Lower Upper  
URINE  
ACR 
(micro 
g/mg) 
5-9  45 48.92 17.41 2.59 43.68 54.14 17.65 61.66 
10-
14 
15 68.74 15.01 3.87 60.42 77.05 23.67 83.64 
15-
19 
12 125.76 43.51 12.56 98.11 153.41 69.73 186.78 
>=20 4 221.77 23.22 11.61 184.81 258.73 190.56 245.56 
Total 76 74.06 49.95 5.73 62.64 85.47 17.65 245.56 
URINE  
ALBUMI
N 
(mg/L) 
5-9  45 33.31 6.54 .97 31.35 35.28 16.35 39.12 
10-
14 
15 48.44 8.72 2.25 43.61 53.27 17.45 53.56 
15-
19 
12 57.19 1.11 .32 56.48 57.90 55.67 59.01 
>=20 4 171.14 8.65 4.32 157.37 184.91 159.45 180.35 
Total 76 47.32 31.52 3.61 40.12 54.53 16.35 180.35 
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GRAPH.8 comparison of smokers and non-smoker subjects for 
microalbuminuria 
 
 
 
 
 
 
84.09% of the smokers of the total smoking subjects had higher urine  
albumin and 15.90% of the total non-smoking subjects had higher urine  
albumin concentration. 
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GRAPH.9 comparison of mean urinary albumin creatinine ratio 
between smokers and non-smokers 
 
 
 
 
95.45 % of smokers had higher urine albumin creatinine ratio (ACR) of 
 the total smoking subjects and 4.54% of non-smokers had higher urine  
Albumin creatinine ratio. 
 
17.10% 
82.89% 
95.45% 
4.54% 
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
URINE ACR
(<30 MICRO g/mg)
URINE ACR
(>30 MICROg/mg)
SMOKERS
NON-SMOKERS
101 
 
 
 
DISCUSSION 
This study was conducted in Government Rajaji Hospital, Madurai which  
is affiliated to Madurai Medical College, Madurai. 120 non diabetic, 
 normotensive and non-obese subjects were taken from the general  
medicine op clinic of the govt. rajaji hospital. The total number of  
smokers with smoking being defined as those who have smoked >20 bidis  
for more than 5 years are 76. The rest of the 44 subjects were age  
matched and taken as the control population. The period of study was 4  
months. 
Age Distribution of the Study Subjects : 
In our study the mean age of the study subjects is 47.27. The minimum 
age is 33 and the maximum age is 64. The mean age for smokers is 47.89 
and the mean age for the non-smokers is 46.18. The p value is 0.169 on 
comparing the two means and hence the two groups are comparable with 
respect to age. In similar study conducted by R.K.Gupta et al in mahatma 
Gandhi medical college and hospital, Jaipur india with a total of 120 
subject, the mean age of smokers is 48.68 and the mean age for non-
smokers is 46.10 which is similar to our study. In the PREVEND study 
conducted in Netherlands the mean age for smokers is around 47. Our 
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study included individuals in the age group from 30 to 70 years. This was 
similar to the study conducted by R.K.Gupta et al. 
Distribution of the baseline physical and biochemical characteristics: 
Body mass index: 
The mean body mass index for the smokers is 22.128 and for the non-
smokers is 22.525. The minimum value is 18.9 and the maximum value is 
24.7. The p value comparing the two means by independent T test is 
0.060. so there was no statistically significant difference between the two 
means. In another study conducted by R.K.Gupta et al the mean BMI in 
smokers was 23.97 and for non-smokers was  24.52. 
Blood pressure: 
The mean value for systolic blood pressure among smokers is 124.16 
mmhg and among non-smokers is 123.73 mmhg. The p value using the 
independent T test is 0.572. There was no statistically significant 
difference between the two means. The mean diastolic blood pressure 
among smokers is 75.50mmhg and the mean diastolic blood pressure 
among non-smokers is 75.61mmhg. The p value comparing the two 
means is 0.867 and so there is no statistically significant difference 
between the two means. In the study conducted by R.K.Gupta the mean 
systolic blood pressure among smokers was 124.40mmhg and among 
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non-smokers was 124.25mmhg. This is similar to our study. The diastolic 
blood pressure among smokers in that same study was 77.35 mmhg 
among smokers and 77.75 mmhg among non-smokers and this is close to 
our study. In the PREVEND study conducted in Netherlands the systolic 
blood pressure mean was around 75 mmhg in non-smokers and 73 mmhg 
in smokers. This was similar to our study. 
Lipid profile: 
The total cholesterol mean for smokers in our study is 151.62 mg/dl and 
the mean for non-smokers is 151.45 mg/dl. The p value comparing these 
two means is 0.846 and hence the difference is not statistically significant. 
The Low density lipoprotein (LDL) mean for smokers is 89.116 mg/dl 
and the mean for non-smokers is 84.977. The p value comparing the two 
means is 0.001. The normal range for LDL is between 70 and 100 mg/dl. 
and so this difference is not clinically significant. The mean value for 
triglyceride for smokers is 126.99 mg/dl  and for non-smokers is 123.07 
mg/dl. The p value comparing these two is 0.014. The mean value for 
very low density lipoprotein for smokers is 25.397 mg/dl and for non-
smokers is 24.614 mg/dl. The p value comparing these two means is 
0.014. Hence the differences were not statistically significant. In the study 
conducted by R.K.Gupta et al the mean value for smokers for LDL and 
TG were 88.48 mg/dl and 115.30 mg/dl respectively. The mean LDL for 
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non-smokers for LDL and TG were 85.05mg/dl and 119.14 mg/dl 
respectively. These values were similar to our study. The HDL mean for 
smokers is 37.05 mg/dl and the mean for non-smokers is 42 mg/dl. The p 
value comparing these two means is 0.001 which is statistically 
significant. This difference is important because the normal range for 
HDL is between 40 and 60 mg/dl. so the smokers in our study had 
significantly low HDL when compared to the non-smokers group. Low 
HDL in smokers has been reported in many studies. Similar results were 
obtained in the study conducted by R.K.GUPTA et al in which smokers 
had a mean HDL of 36.66 mg/dl. A study conducted by kavita S.gamit et 
al including 130 patients in which lipid profile among smokers were 
studied showed a similar result with a low HDL among the smoking 
population. Another study comparing 50 smokers and 50 healthy 
volunteers conducted by N.S. neki al also showed significant reduction in 
HDL levels among smokers. 
Renal parameters: 
The mean value for serum urea is 24.46 mg/dl for smokers and 25.39 
mg/dl for non-smokers. The  P value comparing the means is 0.294. Thus 
the difference is not statistically significant. The mean value for serum 
creatinine for smokers is 0.75 and the mean value for the non-smoking 
group is 0.74mg/dl. The p value is 0.701. Thus the difference is not 
105 
 
statistically significant. The creatinine clearance mean value for smokers 
is 102.310 ml/min/1.71m2 and for non-smokers is 105.355 
ml/min/1.72m2. The p value comparing the means is 0.535. hence the 
difference is not statistically significant. 
    Hence the two groups were comparable in all parameters except for 
HDL levels. 
Comparison of urine microalbumin between study and control: 
In this study which contains 120 subjects. 76 were smokers and 44 were 
non-smokers. In this study the number of smoking subjects who had high 
urine albumin levels (>20mg/L) were 69(90.8%) and the number of non-
smoking subjects who had high urine albumin levels were 7(15.9%). The 
microalbuminuria was directly related to the amount of smoking  in pack 
years.  The mean urine albumin for smokers is 47.3271 mg/L and the 
mean urine albumin for non-smokers is 18.9402 mg/L. The chi square P 
value comparing these two means is <0.001.Hence the difference is 
statistically significant and this shows that smokers had significantly high 
urine albumin levels when compared to non-smokers. The mean urinary 
albumin for smokers related to pack years is as follows, 
1)5-9 pack years = 33.38mg/L 
2)10-14 pack years = 48.84mg/L 
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3)15-19 pack years = 57.19 mg/L 
4)>20 pack years = 171.15 mg/L 
9.2% of smokers and 84.1 % of non-smokers had normal urine albumin 
levels. In the study conducted by R.K.gupta et al which included 120 
subjects with 80 smokers and 40 non-smokers, 91.25%(73) of smokers 
and 22.5%(9) non-smokers had high urine albumin levels. In the 
PREVEND study conducted in Netherlands also showed that non-diabetic 
normotensive and non-obese smokers had a significantly higher urine 
albumin levels when compared to non-smokers. In another study 
conducted by Hitesh shah et al in Gujarat comparing 50 tobacco and 50 
healthy volunteers the tobacco chewers had significantly high mean urine 
albumin of 373±13mg/L when compared to healthy volunteers. In a 
Japanese study that included 10,118 middle aged individuals with normal 
renal parameters and no proteinuria at entry showed that after a followup 
of six years smokers had a higher incidence of proteinuria and they were 
at a 1.51 time high risk of developing proteinuria than their non-smoking 
counterparts. 
 
 
107 
 
Comparison of Urine albumin creatinine ratio(ACR) between study 
and control group: 
The number of smoking subjects who had high urine albumin creatinine 
ratio were 63(82.9%) and the number of non-smoking subjects who had 
high urine albumin creatinine ratio were 2(4.5%). 13(17.1%) of smokers 
and 42(95.5%) of non-smokers had urine albumin creatinine ratio within 
normal limits. The mean urinary albumin creatinine ratio for smokers is 
74.0617 micro g/mg and the mean urinary albumin creatinine ratio for 
non-smokers is 20.6566 micro g/mg. The p value by chi square test 
comparing these two means is <0.001. Hence the difference is statistically 
significant and this shows that smokers have significantly high urinary 
albumin creatinine ratio when compared to non-smokers. The mean 
urinary albumin related to pcak years of smoking is as follows, 
1) 5-9 pack years = 48.92 micro g/mg 
2) 10-14 pack years = 68.74 micro g/mg 
3) 15-19 pack years = 125.76 micro g/mg 
4) >20 pack years = 221.77 micro g/mg. 
This shows that the urinary albumin creatinine ratio is directly 
related to the number of pack years of smoking.  
In the study conducted by R.K.gupta et al including 120 
subjects(80 smokers and 40 non-smokers), 64(80%) smokers and 2 
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non-smokers(5%) had high urinary albumin creatinine ratio which 
is similar study. 
A recent study has showed that subjects with both systemic hypertension 
and left ventricular hypertrophy smoking more than 20 cigarettes per day 
had a 1.6 fold higher prevalence of microalbuminuria and a 3.7 fold 
higher prevalence of macroalbuminuria. Several similar studies have 
documented that smoking is an independent risk factor for micro/macro 
albuminuria and progression to end stage kidney disease. 
One of the mechanisms by which smoking causes albuminuria is by the 
formation of advanced glycation end products (AGEPs). When reducing 
sugars react with the amino groups of lipids, nucleic acids and plasma 
proteins, the advanced glycation end products are formed. The 
compounds increase the vascular permeability and are also responsible for 
the progression of vasculopathy and nephropathy in end stage diabetic 
kidney disease. Glycotoxins present in the smoke react with plasma and 
tissue proteins and lead to AGEP formation which has the same effect on 
renal and systemic vessels. One another mechanism by which smoking 
affects the kidney is by insulin resistance. Studies have shown that 
smoking can induce insulin resistance in non-diabetic subjects. Insulin 
resistance has been linked with albuminuria and renal function 
detoriation. Both these machansims act through inducing endothelial 
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damage thus bringing about an imbalance between contracting and 
relaxing substances in the endothelium. Studies have shown that  smokers 
have high endothelin concentration and low concentration of vasodilatory 
substances. 
In our study non-diabetic, normotensive and non-obese smokers had a 
higher mean urinary albumin concentration when compared to non-
smokers and the mean urinary albumin in smokers were directly related to 
the pack years of smoking. Smokers also had a high urinary albumin 
creatinine ratio when compared to non-smokers when compared to non-
smokers and the urine ACR was directly related to the pack years of 
smoking. In our study all the baseline biochemical parameters were 
comparable except the HDL levels which were significantly low when 
compared to non-smokers. 
The limitations in our study were a small number of subjects, single 
centre data and screening with one timed urine samples. 
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CONCLUSION  
 Normotensive and non-diabetic smokers have significantly higher 
levels of urine albumin when compared to non-smokers. 
 Normotensive and non-diabetic smokers have significantly higher 
levels of urine albumin creatinine ratio (ACR) when compared to 
non-smokers. 
 The high urine albumin levels and high urine albumin creatinine 
ratio (ACR) levels are directly related to the quantity of smoking 
expressed in pack years. 
 The proportion of smokers having high urine albumin levels is 6 
fold times the non-smokers and the proportion of smokers having 
high urine albumin creatinine ratio (ACR) is 18 fold times the non-
smokers. 
 Smokers had significantly low HDL levels when compared to non-
smokers. 
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SUMMARY 
Smoking has major adverse effects on health and it predisposes to 
ischemic heart disease, chronic bronchitis, emphysema, stroke and 
tumors of lung, gastrointestinal system, urinary tract , etc. smoking 
reduces renal blood flow and long term smoking increases the risk 
of progression to end stage renal disease. Smoking causes a 
transient rise in systolic blood pressure, reduces glomerular 
filtration rate and renal plasma flow. It increases the risk of renal 
function deterioration in elderly. Various studies has shown that 
smoking causes a dose dependent increase in urine albumin 
excretion. It increases the risk of albuminuria and renal function 
deterioration in the general population. Stopping the habit of 
smoking reverses these adverse effects to a significant extent in the 
long term. In a study on lean subjects with essential hypertension it 
was found that the microalbuminuria prevalence in smokers was 
twice the amount found in non-smokers. In smokers with diabetes 
mellitus the microalbuminuria prevalence is increased, the time 
period between the onset of albuminuria and diabetes mellitus is 
shortened, the risk of progression from microalbuminuria to 
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macroalbuminuria is increased, the risk of progression to end stage 
renal disease is increased and the risk of ischemic nephropathy is 
increased. 
In non-diabetic renal disease such a lupus nephritis and IgA 
nephropathy the risk of progression to end stage renal disease in 
increased in smokers. smoking is also reported to increase the risk 
of cholesterol microembolism and thus increases the of progression 
of ischemic nephropathy. Smoking also reduces the allograft 
survival in renal transplant recipients.  Multiple studies have shown 
that microalbuminuria is an independent risk factor for 
cardiovascular  disease and renal disease. It a marker of endothelial 
dysfunction and it predicts the future risk of progression to end 
stage renal failure, progression to overt proteinuria and increase in 
serum creatinine. The heart outcome and prevention study (HOPE) 
study has shown that smoking was an independent predictor of 
microalbuminuria in both diabetic and non-diabetic population. The 
prevention of renal and vascular end stage disease or PREVEND 
study showed that smokers had a high statistically significant urine 
albumin excretion when compared to nonsmokers. 
In our study which included 120 subjects from govt.rajaji hospital, 
76 were smokers and 44 were non-smokers. microalbuminuria was 
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defined as urine albumin excretion above 20mg/L and urine 
albumin creatinine ratio was defined as a value above 30 micro 
g/mg. 69 smokers(90.8%) of smokers and 7non-smokers (15.9%) 
had microalbuminuria. 63 smokers(82.9%)  of smokers and 2 non 
smokers (4.5%) had high urine albumin creatinine ratio(ACR). The 
mean urine albumin in smokers was 47.3271 mg/L and the mean 
urine albumin in non-smokers is 18.9402 mg/L. The P value  using 
chi square test is <0.001. The mean urinary albumin creatinine ratio 
is 74.0617 and for non-smokers is 20.6566. The p value using the 
chi square test is <0.001. Hence this shows that the number of 
smokers having microalbuminuria and the high urinary albumin 
creatinine ratio is significantly high than the non-smoking subjects. 
Our study also shows that the microalbuminuria and high urine 
albumin creatinine ratio are directly proportional to the number of 
pack years of smoking, Which means that urine albumin excretion 
and albumin creatinine ratio increase with the duration of smoking. 
Our study has also shown that smokers had statistically significant 
low HDL when compared to non-smokers. This topic needs further 
attention and further research is needed on the high prevalence of 
smoking addiction in the indian community and its impact on the 
renal function and cardiovascular risk. 
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PROFORMA 
 
Name:                                     Age/Sex:                        Occupation: 
                                                 OP.No 
Address: 
 
Past history:    
    DM, HTN, CAD, CVA, CKD, Hypothyroidism,   Nephrotic syndrome,
                                              
 
Drug history: H/o any drug intake(anti hypertensives, OHAs, 
cardiovascular drugs) 
 
Family history: CAD, Obesity, renal disorders 
 
Personal history:- H/o substance abuse 
Smoking in pack years: 
Clinical examination: 
 
General examination: 
Pallor,       Clubbing,     Icterus,   corneal arcus , xanthoma                                                             
Lymphadenopathy,   Cyanosis  ,   Pedal oedema  
 Ht  (in meter):             weight (in kg) :        BMI: 
122 
 
Fundus examination:  Right eye :                  Left eye: 
Vitals: 
Pulse:                                         BP: 
RR:                                            Temperature: 
Systemic examination: 
      CVS  : 
      RS   : 
      ABDOMEN : 
      CNS 
Laboratory investigations: 
1)Fasting blood sugar (Venous blood sample for glucose analysis) 
2)Total cholesterol 
3)High density cholesterol 
4)Low density cholesterol 
5)very low density cholesterol 
6)Triglycerides 
7)Blood urea 
8)Serum creatinine 
9)Urine albumin and albumin-creatinine ratio 
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ABBREVIATIONS 
HDL   -    High Density Lipoprotein 
LDL   -    Low Density Lipoprotein 
VLDL  -  Very Low Density Lipoprotein 
TG     -     Triglycerides 
TC     -     Total cholesterol 
PGF2 -     8-iso-prostaglandin F2 
TBARS-   Thiobarbituric acid reactive substances 
GSH  -    Glutathione 
PMN  -   Poly morphonuclear neutrophil. 
CRP  -    C-reactive protein 
TNF   -    Tumour necrosis factor 
t-PA  -    tissue plasminogen activator 
PAI-I   -  Plasminogen activator inhibitor 
PAH   -   Poly aromatic hydrocarbons 
NNN   -  N-nitrosonornicotine 
NNK  -   N-nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-  
               butanone. 
DNA  -    Deoxy ribo nucleic acid. 
LIFE  -    Losartan intervention for endpoint reduction in  
                Hypertension. 
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AER  -  Albumin excretion rate. 
GFR  -   Glomerular filtration rate. 
ACTH -  Adrenocorticotropic hormone 
IDNT  -  Irbesartan diabetic nephropathy trial. 
ANCA -  Anti-neutrophil cytoplasmic antibody. 
PREVEND -  Prevention of renal and vascular endstage disease 
                       intervention. 
cGMP  -  cyclic guanosine monophosphate. 
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1 KRISHNAN M 42 1.65 62 22.77 124 70 80 148 89.2 36 114 22.8 
2 KARUPPAIYAH M 45 1.64 61 22.68 122 72 76 156 92.4 38 128 25.6 
3 SITARAM M 44 1.66 63 22.86 124 74 78 160 79.2 56 124 24.8 
4 MUNIYAPPAN M 51 1.65 63 23.14 128 78 82 147 86 37 120 24 
5 CHINNAYAH M 45 1.63 62 23.34 120 76 90 148 82.4 42 118 23.6 
6 RAMAR M 50 1.6 59 23.05 128 74 92 150 79.6 46 122 24.4 
7 SELVAM M 48 1.64 60 22.31 128 78 95 152 88.4 39 123 24.6 
8 RAMACHAND M 54 1.64 58 21.56 126 80 90 155 96 34 125 25 
9 ALI 
MUHAMMED 
M 44 1.65 59 21.67 128 78 76 156 98.6 33 122 24.4 
10 KALLIAPPAN M 53 1.64 60 22.31 122 70 78 156 92.8 40 116 23.2 
11 RAMAN M 46 1.68 58 20.55 124 72 80 150 88.4 38 118 23.6 
12 MALAISAMY M 56 1.67 60 21.51 130 74 82 147 86.6 35 127 25.4 
13 DURAI RAJ M 46 1.65 58 21.30 128 76 85 146 84 38 120 24 
14 SIVA PRAKASH M 52 1.66 60 21.77 126 78 87 158 98.4 36 118 23.6 
15 KUMARESAN M 42 1.62 62 23.62 128 70 76 150 89.8 37 116 23.2 
16 MUTHU  M 55 1.65 60 22.04 126 72 78 148 87 38 115 23 
17 PALANI M 40 1.62 55 20.96 122 76 88 146 80.4 43 113 22.6 
18 GANESAN M 53 1.65 60 22.04 132 74 76 144 86.2 35 114 22.8 
19 KULANTHAI M 37 1.62 58 22.10 118 78 86 148 85.6 39 117 23.4 
20 CHELLAIYAH M 52 1.62 57 21.72 126 76 74 150 91.4 34 123 24.6 
21 MEGAVARNAN M 38 1.59 55 21.76 116 74 83 152 95 33 120 24 
22 BHAGADUR M 53 1.64 60 22.31 114 78 90 154 91 37 130 26 
23 RAJA M 54 1.65 57 20.94 118 80 91 153 90.8 36 131 26.2 
24 PAULSAMY M 39 1.66 66 23.95 120 80 88 154 88 42 120 24 
25 MUTHUSAMY M 63 1.68 64 22.68 130 82 76 156 92 38 130 26 
26 DURAI RAJ M 41 1.63 65 24.46 126 80 79 148 88.4 36 118 23.6 
27 ALAGARSAMY M 51 1.64 62 23.05 120 78 85 147 89 34 120 24 
28 RAMAR M 47 1.67 60 21.51 128 78 97 148 88.2 35 124 24.8 
29 RAJA M 51 1.62 57 21.72 122 70 83 149 89.4 36 118 23.6 
30 MURUGAN M 46 1.64 56 20.82 120 74 95 147 86.8 37 116 23.2 
31 RAJAGOPAL M 53 1.65 55 20.20 120 76 76 148 91 34 115 23 
32 ALLABAKS M 40 1.63 51 19.20 120 74 73 148 88 36 120 24 
33 SONAI M 52 1.66 52 18.87 122 76 86 146 86.8 34 126 25.2 
34 VELU M 45 1.69 57 19.96 124 76 89 148 87.2 38 114 22.8 
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35 PRABHAKARAN M 48 1.65 62 22.77 126 78 86 146 82.4 39 123 24.6 
36 LAKSHMANAN M 40 1.63 54 20.32 128 80 85 148 82.2 40 129 25.8 
37 PERIYASAMY M 50 1.64 60 22.31 126 80 89 150 86.8 40 116 23.2 
38 KUMAR M 34 1.63 60 22.58 120 70 90 151 89.4 36 128 25.6 
39 MARIMUTHU M 59 1.68 57 20.20 118 72 95 153 90.2 38 124 24.8 
40 PITCHAIRAJAN M 33 1.63 58 21.83 126 76 97 154 94 34 130 26 
41 CHELLADURAI M 57 1.69 59 20.66 120 70 89 149 92.2 33 119 23.8 
42 RAJA M 37 1.65 59 21.67 126 72 90 150 87.2 36 134 26.8 
43 RAMAN M 56 1.63 55 20.70 116 70 94 153 94.4 35 118 23.6 
44 SELVAM M 45 1.66 60 21.77 116 70 97 160 98 38 120 24 
45 AASAI M 60 1.62 59 22.48 120 72 76 158 97.4 36 123 24.6 
46 MAYANDI M 47 1.65 59 21.67 128 74 78 154 86 43 125 25 
47 MANOKARAN M 54 1.62 56 21.34 124 74 83 160 99.4 35 128 25.6 
48 SANTHAKUMAR M 42 1.62 60 22.86 126 76 85 156 92 37 135 27 
49 CHELLAM M 58 1.65 62 22.77 124 78 89 154 95.4 35 118 23.6 
50 BALAMURUGAN M 44 1.65 61 22.41 120 70 80 148 79.6 45 117 23.4 
51 MUNIYANDI M 52 1.64 62 23.05 118 70 76 147 87.8 32 136 27.2 
52 RAJAGOPAL M 44 1.65 60 22.04 128 76 89 148 90.6 30 137 27.4 
53 GURUSAMY M 51 1.67 59 21.16 124 76 83 149 79.2 42 139 27.8 
54 SUNDAR M 45 1.65 56 20.57 126 76 87 147 80 39 140 28 
55 MANOKARAN M 64 1.61 58 22.38 120 70 82 148 88.2 34 129 25.8 
56 MOORHTY M 40 1.62 59 22.48 128 80 80 147 82.6 36 142 28.4 
57 KARUPUSAMY M 60 1.64 60 22.31 124 70 87 148 85.6 35 137 27.4 
58 PANDI M 44 1.63 62 23.34 126 76 83 149 83.4 38 138 27.6 
59 SUBRAMANI M 59 1.65 62 22.77 128 80 87 155 90 37 140 28 
60 LASHMANAN M 45 1.65 62 22.77 128 76 89 156 94.4 33 143 28.6 
61 ALGARSAMY M 55 1.65 65 23.88 126 80 90 153 90.8 35 136 27.2 
62 MUNIYASAMY M 40 1.65 62 22.77 120 72 92 149 86.2 37 129 25.8 
63 MURUGESH M 56 1.64 62 23.05 128 76 95 160 98.2 38 119 23.8 
64 PRAKASH M 47 1.63 60 22.58 122 74 97 161 98 35 140 28 
65 KATHIR M 55 1.65 62 22.77 120 72 80 161 93 39 145 29 
66 RATHINAM M 45 1.66 63 22.86 124 76 76 158 94 34 150 30 
67 RAJA M 46 1.64 62 23.05 128 76 84 150 84.2 36 149 29.8 
68 DEVARAJ M 48 1.64 60 22.31 126 74 89 152 86.4 37 143 28.6 
69 MANI M 45 1.65 64 23.51 126 78 83 148 80.4 38 148 29.6 
70 RAJ KUMAR M 48 1.63 60 22.58 128 80 98 146 84 35 135 27 
71 AHMED M 46 1.63 60 22.58 128 78 82 149 89 34 130 26 
72 YUSUF M 44 1.65 64 23.51 130 82 81 160 96.6 37 132 26.4 
73 MANI M 42 1.62 61 23.24 128 80 89 158 95 36 135 27 
74 DHANRAJ M 42 1.65 60 22.04 128 82 84 159 93 38 140 28 
75 AJITH M 40 1.65 62 22.77 124 76 78 148 84.6 36 137 27.4 
76 KUMAR M 45 1.67 62 22.23 126 78 72 156 97 35 120 24 
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1 KRISHNAN M 42 33 0.8 105.49 32.02 56.49 7 
2 KARUPPAIYAH M 45 22 0.8 100.61 35.03 57.83 7 
3 SITARAM M 44 34 0.8 105.00 35.78 60.56 6 
4 MUNIYAPPAN M 51 25 0.8 97.34 31.56 58.58 7 
5 CHINNAYAH M 45 26 0.9 90.90 37.12 59.21 5 
6 RAMAR M 50 17 0.7 105.36 50.21 66.45 12 
7 SELVAM M 48 18 0.7 109.52 51.34 68.67 11 
8 RAMACHANDRAN M 54 20 0.7 98.97 57.45 180.81 17 
9 ALI MUHAMMED M 44 22 0.7 112.38 18.25 20.45 8 
10 KALLIAPPAN M 53 19 0.7 103.57 50.45 57.45 14 
11 RAMAN M 46 18 0.7 108.17 34.78 60.13 8 
12 MALAISAMY M 56 24 0.7 100.00 56.25 100.56 15 
13 DURAI RAJ M 46 34 0.8 94.65 37.89 61.23 7 
14 SIVA PRAKASH M 52 26 0.7 104.76 32.67 60.99 9 
15 KUMARESAN M 42 22 0.8 105.49 33.99 59.54 6 
16 MUTHU  M 55 20 0.7 101.19 53.24 70.76 14 
17 PALANI M 40 28 0.8 95.49 18.26 22.56 8 
18 GANESAN M 53 20 0.7 103.57 51.34 80.56 14 
19 KULANTHAIVEL M 37 18 0.7 118.53 35.89 59.76 7 
20 CHELLAIYAH M 52 30 0.8 87.08 34.67 59.86 9 
21 MEGAVARNAN M 38 32 0.8 97.40 17.25 19.34 7 
22 BHAGADUR M 53 30 0.7 103.57 52.31 74.35 13 
23 RAJA M 54 28 0.7 97.26 55.76 99.56 19 
24 PAULSAMY M 39 24 0.9 102.87 37.45 58.58 8 
25 MUTHUSAMY M 63 26 0.7 97.78 180.35 190.56 25 
26 DURAI RAJ M 41 30 0.8 111.72 36.99 26.45 9 
27 ALAGARSAMY M 51 32 0.8 95.80 35.46 60.98 8 
28 RAMAR M 47 28 0.7 110.71 31.45 61.25 7 
29 RAJA M 51 27 0.7 100.65 32.17 57.65 9 
30 MURUGAN M 46 26 0.7 104.44 37.42 59.74 7 
31 RAJAGOPAL M 53 23 0.7 94.94 58.75 186.78 17 
32 ALLABAKS M 40 20 0.7 101.19 16.35 18.45 8 
33 SONAI M 52 26 0.6 105.93 36.77 58.54 9 
34 VELU M 45 30 0.7 107.44 35.49 56.49 7 
35 PRABHAKARAN M 48 20 0.8 99.03 53.56 82.53 13 
36 LAKSHMANAN M 40 18 0.8 93.75 38.49 19.45 7 
37 PERIYASAMY M 50 17 0.7 107.14 50.78 83.64 14 
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38 KUMAR M 34 19 0.8 110.42 38.45 18.65 6 
39 MARIMUTHU M 59 30 0.7 91.61 159.45 220.45 25 
40 PITCHAIRAJAN M 33 23 0.8 107.74 18.45 20.45 7 
41 CHELLADURAI M 57 22 0.6 113.36 58.11 175.45 18 
42 RAJA M 37 20 0.7 120.58 39.12 57.74 7 
43 RAMAN M 56 19 0.7 91.67 55.67 167.65 18 
44 SELVAM M 45 26 0.7 113.10 37.13 59.83 6 
45 AASAI M 60 25 0.6 109.26 59.01 156.56 18 
46 MAYANDI M 47 28 0.8 95.26 36.65 61.45 8 
47 MANOKARAN M 54 29 0.7 95.56 51.21 75.68 14 
48 SANTHAKUMAR M 42 30 0.7 116.67 36.87 60.54 8 
49 CHELLAM M 58 32 0.7 100.87 57.12 98.45 17 
50 BALAMURUGAN M 44 25 0.9 90.37 36.74 57.98 9 
51 MUNIYANDI M 52 28 0.7 108.25 49.56 80.41 13 
52 RAJAGOPAL M 44 24 0.8 100.00 36.73 19.1 7 
53 GURUSAMY M 51 31 0.7 104.19 47.67 54.76 13 
54 SUNDAR M 45 26 0.8 92.36 37.64 61.66 7 
55 MANOKARAN M 64 28 0.8 76.53 172.45 245.56 26 
56 MOORHTY M 40 23 0.8 102.43 17.45 23.67 13 
57 KARUPUSAMY M 60 20 0.7 95.24 172.34 230.54 24 
58 PANDI M 44 26 0.8 103.33 35.23 60.43 7 
59 SUBRAMANI M 59 23 0.8 87.19 57.21 96.56 19 
60 LASHMANAN M 45 25 0.8 102.26 32.99 56.78 8 
61 ALGARSAMY M 55 23 0.7 109.62 57.46 94.57 18 
62 MUNIYASAMY M 40 17 0.7 123.02 37.56 23.6 7 
63 MURUGESH M 56 20 0.7 103.33 57.56 69.73 17 
64 PRAKASH M 47 18 0.8 96.88 48.86 68.34 13 
65 KATHIR M 55 23 0.8 91.49 55.98 82.51 18 
66 RATHINAM M 45 27 0.8 103.91 37.65 54.78 8 
67 RAJA M 46 20 0.8 101.18 33.29 59.11 8 
68 DEVARAJ M 48 21 0.7 109.52 48.97 73.45 14 
69 MANI M 45 22 0.7 120.63 34.44 58.74 9 
70 RAJ KUMAR M 48 28 0.8 95.83 49.67 70.42 13 
71 AHMED M 46 31 0.9 87.04 37.11 58.54 7 
72 YUSUF M 44 25 0.9 94.81 36.65 59.87 8 
73 MANI M 42 22 0.8 103.78 35.23 20.16 7 
74 DHANRAJ M 42 20 0.7 116.67 36.75 60.54 8 
75 AJITH M 40 18 0.8 107.64 16.67 17.65 7 
76 KUMAR M 45 29 0.8 102.26 34.77 59.54 8 
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1 MANI M 41 1.64 64 23.80 126 70 78 149 84 42 115 23 
2 MURUGAN M 44 1.63 64 24.09 124 71 76 155 85 41 129 25.8 
3 THAYUMANAV
AN 
M 44 1.65 65 23.88 126 74 78 160 85 42 126 25.2 
4 MOHAN M 50 1.67 63 22.59 126 76 80 148 85 43 122 24.4 
5 MUTHUVEL M 45 1.65 67 24.61 118 76 88 149 85 45 119 23.8 
6 RAMESH M 48 1.6 59 23.05 130 80 90 151 85 42 123 24.6 
7 KULANTHAIVEL M 48 1.61 59 22.76 126 78 90 153 85 40 124 24.8 
8 MARUDHAN M 52 1.6 59 23.05 128 80 90 156 85 42 126 25.2 
9 ABDUL  M 46 1.59 55 21.76 126 78 74 159 85 40 123 24.6 
10 BALA M 52 1.62 61 23.24 120 72 76 157 85 40 120 24 
11 MURUGUAN M 45 1.67 54 19.36 126 72 78 149 85 45 120 24 
12 JAFFER M 45 1.66 63 22.86 132 80 80 148 85 42 128 25.6 
13 RAMESH M 45 1.7 58 20.07 126 80 84 147 85 41 121 24.2 
14 MUTHUVEL M 40 1.71 60 20.52 128 78 86 159 85 40 119 23.8 
15 PALANIVEL M 41 1.57 61 24.75 126 70 75 151 85 43 118 23.6 
16 VELU M 54 1.58 60 24.03 128 72 75 149 85 42 120 24 
17 PARAMSIVAM M 41 1.6 55 21.48 124 80 85 147 85 41 114 22.8 
18 CHINNARAJ M 52 1.64 60 22.31 130 74 75 145 85 42 118 23.6 
19 ILUMALAIYAN M 38 1.62 59 22.48 120 76 84 149 85 43 118 23.6 
20 AJITH KUMAR M 51 1.62 59 22.48 124 76 73 151 85 42 124 24.8 
21 DHANAM M 39 1.59 57 22.55 118 74 82 153 85 41 121 24.2 
22 MANI M 44 1.62 58 22.10 116 72 88 155 85 42 131 26.2 
23 KARTHIK M 53 1.65 58 21.30 120 80 90 154 85 43 132 26.4 
24 CHELLADURAI M 39 1.65 65 23.88 122 80 87 156 85 42 121 24.2 
25 SHANMUGAM M 62 1.65 64 23.51 132 80 75 157 85 40 131 26.2 
26 VELAYUDHAM M 41 1.62 64 24.39 128 80 75 149 85 40 126 25.2 
27 MARIYAPPAN M 50 1.63 62 23.34 122 78 84 147 85 42 121 24.2 
28 PALANIYAPPAN M 46 1.66 60 21.77 126 80 95 149 85 42 126 25.2 
29 MICHAEL RAJ M 50 1.61 58 22.38 120 70 82 150 85 43 119 23.8 
30 KALAIRAJAN M 45 1.63 56 21.08 118 74 94 148 85 42 122 24.4 
31 KURUVAN M 51 1.64 60 22.31 122 76 75 149 85 41 122 24.4 
32 STEPHEN 
DHANPAL 
M 40 1.62 57 21.72 118 74 72 149 85 41 121 24.2 
33 BALAMURUGAN M 51 1.65 58 21.30 120 76 85 147 85 41 125 25 
34 VADAMALAI M 44 1.68 60 21.26 124 76 86 149 85 41 118 23.6 
35 KANNAN M 46 1.69 62 21.71 126 80 85 147 85 42 121 24.2 
36 MALAISAMY M 41 1.59 58 22.94 126 80 84 149 85 43 130 26 
130 
 
37 BALU M 48 1.63 60 22.58 124 78 88 151 85 45 118 23.6 
38 NAGARATHINA
M 
M 36 1.62 60 22.86 122 70 88 150 85 42 126 25.2 
39 SELVARAJ M 57 1.67 63 22.59 120 72 90 154 85 45 124 24.8 
40 SELVAM M 36 1.62 60 22.86 124 80 96 155 85 44 132 26.4 
41 ABDULLAH M 54 1.68 64 22.68 120 70 88 150 85 43 124 24.8 
42 KANNAN M 38 1.64 60 22.31 124 72 85 151 85 42 136 27.2 
43 LOGU M 55 1.62 59 22.48 120 72 93 152 85 42 120 24 
44 JUSTIN 
SAGAYARAJ 
M 44 1.65 60 22.04 118 70 94 161 85 41 121 24.2 
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1 MANI M 41 33 0.8 110.00 17.21 18.99 
2 MURUGAN M 44 23 0.8 106.67 16.02 19.25 
3 THAYUMANAVAN M 44 34 0.8 108.33 17.03 20.65 
4 MOHAN M 50 26 0.8 98.44 16.04 16.75 
5 MUTHUVEL M 45 27 0.8 110.50 17 22.36 
6 RAMESH M 48 18 0.8 94.24 15.01 24.52 
7 KULANTHAIVEL M 48 18 0.7 107.70 16.02 19.04 
8 MARUDHAN M 52 24 0.7 103.02 32.67 17.89 
9 ABDUL  M 46 24 0.7 102.58 15.04 21.76 
10 BALA M 52 20 0.8 93.19 31.23 23.76 
11 MURUGUAN M 45 20 0.7 101.79 15.33 24.98 
12 JAFFER M 45 24 0.8 103.91 16.05 20.03 
13 RAMESH M 45 34 0.8 95.66 17.11 22.85 
14 MUTHUVEL M 40 28 0.7 119.05 18 19.54 
15 PALANIVEL M 41 24 0.7 119.82 17.34 18.54 
16 VELU M 54 22 0.7 102.38 15.99 19.54 
17 PARAMSIVAM M 41 28 0.8 94.53 18.1 19.34 
18 CHINNARAJ M 52 22 0.7 104.76 35.54 20.42 
19 ILUMALAIYAN M 38 20 0.7 119.40 16.02 21.43 
20 AJITH KUMAR M 51 30 0.8 91.16 17.9 18.53 
21 DHANAM M 39 32 0.8 99.95 13.56 16.83 
22 MANI M 44 32 0.7 110.48 17.01 17.65 
23 KARTHIK M 53 28 0.7 100.12 15.23 20.65 
24 CHELLADURAI M 39 26 0.8 113.98 15.64 21.67 
25 SHANMUGAM M 62 28 0.7 99.05 45.11 40.54 
26 VELAYUDHAM M 41 30 0.8 110.00 16.04 18.65 
27 MARIYAPPAN M 50 32 0.8 96.88 15.01 19.65 
28 PALANIYAPPAN M 46 28 0.8 97.92 17.49 16.56 
29 MICHAEL RAJ M 50 27 0.7 103.57 12.45 15.65 
30 KALAIRAJAN M 45 28 0.7 105.56 31.07 18.45 
31 KURUVAN M 51 24 0.7 105.95 16 17.65 
32 STEPHEN DHANPAL M 40 22 0.7 113.10 16.34 18.45 
33 BALAMURUGAN M 51 28 0.7 102.42 17.11 17.57 
34 VADAMALAI M 44 30 0.7 114.29 15.02 20.04 
35 KANNAN M 46 22 0.8 101.18 14.34 18.76 
36 MALAISAMY M 41 19 0.8 99.69 16.34 20.45 
37 BALU M 48 18 0.7 109.52 29.01 18.65 
38 NAGARATHINAM M 36 20 0.8 108.33 15.02 18.46 
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39 SELVARAJ M 57 30 0.7 103.75 34.1 36.21 
40 SELVAM M 36 23 0.8 108.33 15.01 21.75 
41 ABDULLAH M 54 23 0.7 109.21 16.55 22.87 
42 KANNAN M 38 22 0.7 121.43 17.1 19.56 
43 LOGU M 55 20 0.7 99.50 16.1 18.46 
44 JUSTIN SAGAYARAJ M 44 26 0.7 114.29 16.07 23.54 
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